Asta Literature Retrieval: Pathophysiology and clinical mechanisms of Kniest Dysplasia. Core disease mechanisms, molecular and cellular pathways...

This report is retrieval-only and is generated directly from Asta results.

• Papers retrieved: 19
• Snippets retrieved: 20

Relevant Papers

[1] Nasopharyngeal Carcinoma Signaling Pathway: An Update on Molecular Biomarkers

• Authors: W. Tulalamba, T. Janvilisri
• Year: 2012
• Venue: International Journal of Cell Biology
• URL: https://www.semanticscholar.org/paper/307cb9186444d9dad6e2e3b53763be0de76de186
• DOI: 10.1155/2012/594681
• PMID: 22500174
• PMCID: 3303613
• Citations: 93
• Influential citations: 5
• Summary: The molecular signaling pathways in the NPC are discussed for the holistic view of NPC development and progression and the important insights toward NPC pathogenesis may offer strategies for identification of novel biomarkers for diagnosis and prognosis.
• Evidence snippets:
• Snippet 1 (score: 0.390) > In the pregenomic eras, highly integrated and complex circuitry of molecular signaling in NPC pathogenesis was only partially understood. Over the past decade, the knowledge of the molecular mechanisms in NPC carcinogenesis has been rapidly accumulated. Dysregulation and abnormal protein expression of molecules in certain signaling pathways involved in cellular functions including proliferation, adhesion, survival, and apoptosis has been demonstrated in the NPC cells. Detailed information on the complex network in signaling pathway leading to a coordinated pattern of gene expression and regulation in NPC will undoubtedly provide important clues to develop novel prognostic and therapeutic strategies for this cancer. Refining molecular markers into clinically relevant assays may assist in the detection of NPC in asymptomatic patients, as well as stage classification and monitoring disease progression and treatments. Furthermore, selective regulation of particular proteins targeting cancer cell proliferation, invasion, and apoptosis is a hopeful prospect for future anticancer therapy that slow disease progression and improve survival.

[2] EndoCompass Project: Research Roadmap for Calcium and Bone Endocrinology

• Authors: K. Jähn-Rickert, K. Z. Tomsic, A. Anastasilakis, Jean-Philippe Bertocchio, M. L. Brandi et al.
• Year: 2025
• Venue: Hormone Research in Pædiatrics
• URL: https://www.semanticscholar.org/paper/fccbdcae3a86c448632e05f9c38ad2563c14284d
• DOI: 10.1159/000549160
• PMID: 41296665
• PMCID: 12698132
• Summary: This framework identifies crucial investigation areas into metabolic bone disease pathophysiology, prevention, and treatment strategies, ultimately aimed at reducing the burden of these disorders on individuals and society.
• Evidence snippets:
• Snippet 1 (score: 0.372) > Skeletal dysplasias encompass a large spectrum of genetic disorders of the skeleton with abnormal bone growth, structure, or strength [85]. Individually, they are rare but, collectively, due to the large number of skeletal dysplasias (>700), they result in significant morbidity. The underlying pathology remains inadequately understood and the optimal therapy is often undefined, with precision drug treatment targeting the underlying molecular mechanism not available for most skeletal dysplasias. Gene discoveries have increased exponentially, demonstrating the value of advanced genetic tools and motivating further research into the complex pathogenesis of skeletal dysplasias. > However, further basic research is required to uncover the cellular pathology and implicated molecular pathways in various forms of skeletal dysplasia. Understanding the pathophysiology of skeletal dysplasias may also benefit a larger patient population. This is evidenced by anti-sclerostin treatment for osteoporosis [86] which, at present, is in clinical trials for osteogenesis imperfecta. Preclinical data show positive effects on bone mass and strength [87]. > The spectrum of disease manifestations of various skeletal dysplasias in different phases of life and health projections across the life course remain inadequately studied. Research on therapeutic approaches needs to focus not only on correcting the pathophysiology but also, more broadly, on surgical approaches, rehabilitation, functional/environmental adaptations, preventative measures, pain management, psychological support, and quality of life. Patient groups must be involved in identifying these research goals. International registries should be utilized to collect and analyse such data. > A multidisciplinary approach is of particular importance in genetic skeletal disorders, to enable cohesive care throughout the life course. The patients have a range of physical impairments due to their skeletal disorder, but also a disease-specific spectrum of extraskeletal manifestations requiring medical attention. These may include, for example, dental and oral health problems, immune deficiency, impaired hearing, and neurological or ophthalmologic manifestations.

[3] New therapeutic targets in rare genetic skeletal diseases

• Authors: M. Briggs, Peter A. Bell, M. Wright, K. A. Pirog
• Year: 2015
• Venue: Expert Opinion on Orphan Drugs
• URL: https://www.semanticscholar.org/paper/1363107f71ae6d2d60abca471cddf3da5d13644b
• DOI: 10.1517/21678707.2015.1083853
• PMID: 26635999
• PMCID: 4643203
• Citations: 37
• Influential citations: 1
• Summary: An overview of disease mechanisms that are shared amongst groups of different GSDs and potential therapeutic approaches that are under investigation are described to generate critical mass for the identification and validation of novel therapeutic targets and biomarkers.
• Evidence snippets:
• Snippet 1 (score: 0.367) > proteins of the cartilage ECM such as type II collagen [50]. However, emerging knowledge suggests that the primary genetic defect may be less important than the cells' response to the expression of the mutant gene product [107]. Moreover, the largely overlooked response of a cell (i.e. chondrocyte) to the abnormal extracellular environment is also important for disease progression as illustrated by several GSDs discussed in this review. > It is important that 'omics'-based approaches and technologies are systematically applied to the study of rare GSDs so that definitive reference profiles and disease signatures are generated for each phenotype. These can then be used in a Systems Biology approach to identify both common and dissimilar pathological signatures and disease mechanisms. This approach is entirely dependent upon relevant in vitro and in vivo models (and also novel 'disease-mechanism phenocopies' [107]) for testing new diagnostic and prognostic tools and for determining the molecular mechanisms that underpin the pathophysiology so that effective therapeutic treatments can be developed and validated. This approach will eventually lead to personalized treatments and care strategies centred on shared disease mechanisms with the use of relevant biomarkers to monitor the efficacy of treatment and disease progression. > It is vital that all relevant stakeholders are involved from the outset in defining the appropriate outcomes of any potential therapeutic regime. The perceptions of a successful therapy can differ widely between the clinical academic community and the relevant patient-support groups and it is vital that there is engagement on all these issues. > In summary, the identification of causative genes and mutations for GSDs over the last 20 years, coupled with the generation and in-depth analysis of a plethora of relevant cell and mouse models, has derived new knowledge on disease mechanisms and suggested potential therapeutic targets. The fast-evolving hypothesis that clinically disparate diseases can share common disease mechanisms is a powerful concept that will generate critical mass for the identification and validation of novel therapeutic targets and biomarkers.
• Snippet 2 (score: 0.345) > The extensive clinical variability and genetic heterogeneity of GSDs, coupled with complex disease mechanisms, renders this extensive group of rare diseases a bench to bedside challenge. Indeed, this large number of different and highly complex phenotypes makes the identification, validation and development of potential therapies almost impossible for anything other than the most common GSDs. As an alternative approach, we might consider identifying genotype-and/or phenotype-independent 'core disease mechanisms' that are shared amongst families of clinically unrelated GSDs. This approach would allow the focusing of resources into several areas of concerted investigation that have the potential to identify and validate therapeutic targets with a broad application to GSDs, inherited connective tissues as a whole and rare genetic disease in general. Indeed, Jürgen Spranger first suggested the idea of 'bone dysplasia families' in 1985 [124] and proposed that phenotypes with a similar clinical and radiographic phenotype would likely have a similar disease mechanism. Thirty years later, we can now expand upon this pioneering concept and propose that common disease mechanisms can also be shared amongst clinically different phenotypes ('common amongst the rare'). > In this context, ER stress has been associated with a diverse range of genetic diseases and chronic conditions such as skeletal dysplasia (as discussed in this review), myopathy [125], cerebro-vascular [42], kidney [126], ischaemia and cardiovascular diseases [127]. Moreover, ER stress is emerging as a very attractive target that is being successfully exploited in a broad range of diseases including neuropathy, juvenile-onset openangle glaucoma, obesity, diabetes, asthma and epidermolysis bullosa, to name but a few. Historically many GSDs were considered diseases of the ECM and proposed therapeutic interventions involved the removal and/or correction of the relevant mutated gene or abnormal gene product. This was particularly the case with dominant-negative mutations in the large structural proteins of the cartilage ECM such as type II collagen [50]. However, emerging knowledge suggests that the primary genetic defect may be less important than the cells' response to the expression of the mutant gene product [107]. Moreover, the largely overlooked response of a cell (i.e.

[4] Case report: Whole exome sequencing and genome-wide methylation profiling of Czech dysplasia in a Chinese pedigree

• Authors: Mengfei Zhao, Runrun Zhang, Cen Chang, Yehua Jin, Lingxia Xu et al.
• Year: 2023
• Venue: Frontiers in Medicine
• URL: https://www.semanticscholar.org/paper/0b4c5d8d1c1628c4b97fb2a617e56922033a0080
• DOI: 10.3389/fmed.2023.1244888
• PMID: 38020103
• PMCID: 10652562
• Summary: The case of a Chinese woman diagnosed with Czech dysplasia (proband) who carried a variant in the COL2A1 gene is presented and Whole-exome sequencing identified the COL1A1 missense mutation in close relatives of the proband who also exhibited the same disorder.
• Evidence snippets:
• Snippet 1 (score: 0.365) > COL2A1 encodes for the collagen type II alpha 1 chain (6) found in human cartilage and eye vitreous on chromosome 12 (7,8). Type II collagen plays a vital role in endochondral bone formation and growth (9). Mutations in the COL2A1 gene affect endochondral ossification and linear bone growth with structurally abnormal type II collagen (10). Interestingly, there is a wide spectrum of phenotypes that have been attributed to different COL2A1 variants, including achondroplasia, early-onset familial osteoarthritis, congenital vertebral dysplasia, Stickler syndrome, Kniest dysplasia, and Strudwick congenital spine dysplasia (7,11). Recently, a Chinses study found that the p.Arg275Cys mutation in the COL2A1 gene often led to toe malformation and was considered a mutational hotspot for Czech dysplasia (10). This is the first report of Czech dysplasia in the Han Chinese population and therefore expands our epidemiological knowledge of the disorder. In addition, several other disorders, such as achondrogenesis type II, Kniest dysplasia, Legg-Calve-Perthes disease, spondyloepiphyseal dysplasia, and Stickler syndrome, are caused by COL2A1 variants (occurring in different regions of the gene), and therefore, understanding the molecular pathophysiology and clinical presentation of the patients studied in this work can potentially lead to insights for those additional type II collagenopathies. In addition, understanding rare variants with linked phenotypes can aid in the delineation of COL2A1 function, which carries importance for common complex diseases as well, given that osteoarthritis susceptibility has been associated with COL2A1 polymorphisms (12,13). > In this study, we applied whole-exome sequencing to a pedigree and found that the familial disease reported in this study is caused by non-synonymous variants in exon 13 of the protein encoded by COL2A1.

[5] Molecular insights into the premature aging disease progeria

• Authors: Sandra Vidak, R. Foisner
• Year: 2016
• Venue: Histochemistry and Cell Biology
• URL: https://www.semanticscholar.org/paper/60fb3b46bb7e42d5d08cc3b7cbc783b118300c31
• DOI: 10.1007/s00418-016-1411-1
• PMID: 26847180
• PMCID: 4796323
• Citations: 105
• Influential citations: 3
• Summary: Changes in mechanosignaling, altered chromatin organization and impaired genome stability, and changes in signaling pathways, leading to impaired regulation of adult stem cells, defective extracellular matrix production and premature cell senescence are discussed.
• Evidence snippets:
• Snippet 1 (score: 0.363) > The number of molecular biological studies aiming at the identification of lamin-mediated molecular disease mechanisms involved in HGPS increased tremendously following the surprising discovery that LMNA is causally linked to the premature aging disease HGPS in 2003. Despite numerous cellular pathways that were identified to be affected by the expression of the mutant lamin A protein (Fig. 2), the mechanistic details behind these effects are still unclear in most cases. Knowledge based on what was already known on lamin biology before the protein was linked to HGPS and findings on novel roles of lamins in diverse pathways in recent years allowed the launch of translational studies and the efficient search for drug targets and therapeutic approaches within a short time period. The results of the first clinical trials taught us that some improvements of the disease phenotypes can be achieved by FTI treatment, but they also made clear that we need a much better understanding of the underlying disease mechanisms to be able to tackle specific aspects of the disease in a more focused approach. It will also be important to elucidate which of the numerous pathways found to be impaired in HGPS are most relevant for and causally involved in the pathologies, and which ones are just bystanders.

[6] A Roadmap to Gene Discoveries and Novel Therapies in Monogenic Low and High Bone Mass Disorders

• Authors: M. Formosa, D. Bergen, C. Gregson, A. Maurizi, A. Kämpe et al.
• Year: 2021
• Venue: Frontiers in Endocrinology
• URL: https://www.semanticscholar.org/paper/be13ff3ea01dc5719f2c63b2cbf5d9f77bafd659
• DOI: 10.3389/fendo.2021.709711
• PMID: 34539568
• PMCID: 8444146
• Citations: 21
• Summary: The monogenic forms of rare low and high rare bone Mass disorders known to date are described, a roadmap to unravel the genetic determinants of monogenic rare bone mass disorders is provided, using proper phenotyping and genotyping methods are provided, and different genetic validation approaches paving the way for future treatments are described.
• Evidence snippets:
• Snippet 1 (score: 0.360) > Skeletal development is regulated by numerous genetic factors that guide the growth, modeling and remodeling of skeletal structures starting in early fetal development and continuing throughout life. These processes are crucial for attainment of normal height, skeletal patterning, bone shape, and mobility, but also for maintenance of normal bone mass and fracture resistance. Defects in the involved genes result in a large and heterogeneous group of disorders, collectively called skeletal dysplasias, in which the primary features are confined to the skeleton. More than 460 different forms of skeletal dysplasia, most of them monogenic, have been recognized (1). They are estimated to affect approximately 1/5,000 children (2,3), and can have distinct clinical manifestations and course. Clinical outcomes range in severity from neonatal lethality to only mild growth retardation, deformity or fracture risk. Diagnosis is based on growth pattern and other clinical characteristics, skeletal imaging, bone density testing, biochemical diagnostics, and genetic tests. Although the genetic basis has been described and mutations in the responsible genes identified in a significant proportion of these conditions, for several distinct skeletal dysplasia phenotypes the genetic cause is still not known (1). > Within this large group of genetic skeletal disorders, monogenic disorders affecting bone mass comprise an expanding subgroup (1,4). This includes disorders with low bone mass and skeletal fragility, and disorders leading to increased bone mass, both commonly associated with extraskeletal complications (5,6). Due to significant variability in severity, diagnosis can be challenging. Importantly, the underlying molecular genetic mechanisms for these disorders remain inadequately explored and, in several entities, the causative genetic defect, and underlying cellular and molecular pathophysiology are still uncharacterized. > The various skeletal dysplasia delineated to date have provided important information about the molecular pathways governing skeletal health both in these conditions and in the general population, underscoring the significance of new gene discoveries not only for the individuals affected by the monogenic rare bone mass disorder, but also more widely to the musculoskeletal research field (7). Indeed, the large wealth of data generated from monogenic and polygenic bone mass disorders, frailty and other musculoskeletal traits, have led

[7] Role of Transcriptomics in Precision Oncology

• Authors: Ruby Srivastava
• Year: 2024
• Venue: Reports of Radiotherapy and Oncology
• URL: https://www.semanticscholar.org/paper/0bd862558bbb7286336111d9dfd232b5f905d3d9
• DOI: 10.5812/rro-142195
• Citations: 4
• Summary: : Transcriptome profiling is one of the most widely used approaches in the field of multiomics research. It plays a crucial role in the prognostic, diagnostic, and predictive treatment of cancer patients. Novel next-generation sequencing (NGS) technologies permit the identification of cancer biomarkers, gene signatures, and their abnormal expression, affecting oncogenic and molecular targets and novel biomarkers for cancer therapies. Multiomics studies have changed the overall understanding o...
• Evidence snippets:
• Snippet 1 (score: 0.359) > : Transcriptome profiling is one of the most widely used approaches in the field of multiomics research. It plays a crucial role in the prognostic, diagnostic, and predictive treatment of cancer patients. Novel next-generation sequencing (NGS) technologies permit the identification of cancer biomarkers, gene signatures, and their abnormal expression, affecting oncogenic and molecular targets and novel biomarkers for cancer therapies. Multiomics studies have changed the overall understanding of cancer and opened a precise perspective for tumor diagnostics and therapy. The use of these approaches has strengthened our understanding of disease pathophysiology and classifications at the molecular level, including specific interference with drug mechanisms of action. Still, it has limited added value in the clinical setting. The omics data on precision medicine include the application of data from genes, transcripts, and proteins for diagnosis, monitoring of diseases, risk factor determination, counseling, and development of novel therapeutics. Bioinformatics applications have expanded statistics-based analysis toward deriving molecular pathways and process models for characterizing phenotypes and drug action mechanisms. In this review, we will discuss transcriptomics and interference analysis that allows the identification of predictive biomarkers at the molecular level to test drug response and analyze the molecular process interface of disease progression-relevant pathophysiology and mechanism of action to propose predictive biomarkers.

[8] Insights in biomarkers complexity and routine clinical practice for the diagnosis of thyroid nodules and cancer

• Authors: M. G. de Matos, Mafalda Pinto, A. Gonçalves, Sule Canberk, M. J. Bugalho et al.
• Year: 2025
• Venue: PeerJ
• URL: https://www.semanticscholar.org/paper/655de68f1a7e8137dcba8a2046f14dee4f07594d
• DOI: 10.7717/peerj.18801
• PMID: 39850836
• PMCID: 11756370
• Citations: 4
• Summary: The knowledge of genetic and molecular biomarkers has achieved a high level of complexity, and the difficulties related to its applicability determine that their implementation in clinical practice is not yet a reality.
• Evidence snippets:
• Snippet 1 (score: 0.358) > Knowledge of molecular mechanisms implicated in thyroid carcinogenesis has been attained in recent years. Thyroid neoplasm result from alterations in gene expression patterns, which occur due to a gradual accumulation of genetic and epigenetic events. These changes are associated with specific tumor phenotypes and are implicated in disease etiology. Molecular alterations induce the activation of different signaling pathways, such as the mitogen-activated protein kinase (MAPK), and phosphatidylinositol 3-kinase (PI3K/AKT/mTOR), which are involved in and promote carcinogenesis (Hsiao & Nikiforov, 2014). In a few years, the knowledge of molecular mechanisms implicated in thyroid carcinogenesis changed from understanding signaling pathways and identification of a few genes mutations to the knowledge of the main genes implicated in thyroid carcinogenesis, reviewed by De Leo et al. (2024). Genetic changes in thyroid neoplasms were divided in early/driver molecular alterations and late/progression events. Late/ progression events may be associated with early/driver molecular alterations and represent the evolution from well-differentiated to high-grade and undifferentiated carcinoma, being (Pozdeyev et al., 2018). Most frequent gene mutations present in follicular-cell derived thyroid tumors are BRAF, RAS, and TERTp mutations, associate with clinically relevant clinicopathologic features, as shown in Table 3.

[9] Mitochondrial Dysfunction in Diabetes: Shedding Light on a Widespread Oversight

• Authors: F. Iheagwam, A. J. Joseph, E. D. Adedoyin, Olawumi Toyin Iheagwam, Samuel Akpoyowvare Ejoh
• Year: 2025
• Venue: Pathophysiology
• URL: https://www.semanticscholar.org/paper/dbf8042761c1a5fc50f8cd894cc498505abac7cb
• DOI: 10.3390/pathophysiology32010009
• PMID: 39982365
• PMCID: 12077258
• Citations: 23
• Summary: This review aims to elucidate the complex link between mitochondrial dysfunction and diabetes, covering the spectrum of diabetes types, the role of mitochondria in insulin resistance, highlighting pathophysiological mechanisms, mitochondrial DNA damage, and altered mitochondrial biogenesis and dynamics.
• Evidence snippets:
• Snippet 1 (score: 0.356) > The landscape of DM research is continuously evolving, with emerging technologies and approaches offering new insights into the pathophysiology of the disease and potential therapeutic targets. Advancements in omics technologies, encompassing genomes, transcriptomics, proteomics, and metabolomics, have transformed the molecular mechanisms underlying DM [134]. High-throughput sequencing techniques enable comprehensive analysis of genetic variants, gene expression profiles, protein abundance, and metabolite levels associated with DM and its complications [135]. Single-cell omics approaches provide unprecedented resolution and granularity, allowing researchers to dissect cellular heterogeneity and identify novel cell types, subpopulations, and signalling pathways involved in DM pathogenesis. Integrating multi-omics data sets offers a systems-level perspective of DM, unravelling complex networks of molecular interactions and regulatory circuits underlying disease progression [136]. > In addition to omics technologies, advances in imaging modalities, such as MRI, PET, and optical imaging, enable non-invasive visualisation and quantification of metabolic, functional, and structural changes. Molecular imaging probes targeting specific biomarkers and metabolic pathways provide valuable insights into disease mechanisms and treatment responses in preclinical and clinical settings [85]. Despite significant progress in DM research, numerous unanswered questions and knowledge gaps persist, hindering the ability to develop effective prevention and treatment strategies. Key areas requiring further investigation include the role of epigenetics, environmental factors, and the microbiome in DM susceptibility and progression. Moreover, the interaction between environmental cues and genetic predisposition remains incompletely understood, highlighting the need for comprehensive multi-omics studies and large-scale epidemiological analyses to identify gene-environment interactions and modifiable risk factors for DM [137]. Furthermore, the heterogeneity of DM phenotypes and clinical outcomes poses a challenge for personalised medicine approaches, necessitating robust biomarkers and predictive models to stratify patients based on disease subtypes, prognosis, and treatment response [138].

[10] Changes in Serum Proteomic Profiles at Different Stages of Pregnancy Toxemia in Goats

• Authors: M. Uzti̇mür, C. N. Ünal, Gurler Akpinar
• Year: 2025
• Venue: Journal of Veterinary Internal Medicine
• URL: https://www.semanticscholar.org/paper/4b9c488b5dbd65d7b26fd2ad9aed70e8c4b59942
• DOI: 10.1111/jvim.70139
• PMID: 40492724
• PMCID: 12150350
• Summary: Understanding the serum proteome profiles of goats with pregnancy toxemia might help identify the proteomes and pathways responsible for the development of this disease and improve diagnosis and treatment.
• Evidence snippets:
• Snippet 1 (score: 0.356) > The pathophysiology and progression of this disease are not fully understood. > Traditional biomedical research has focused on the analysis of single genes, proteins, metabolites, or metabolic pathways in diseases. This molecular reductionist approach is based on the assumption that identifying genetic variations and molecular components will lead to new treatments for diseases [13][14][15][16]. However, many diseases are complex and multifactorial, and in order to determine the phenotype of such diseases, it is necessary to understand the changes that occur in more than one gene, pathway, protein, or metabolite at the cellular, tissue, and organismal levels [17][18][19]. Therefore, in recent years, proteomics, as one field of multi-omics technologies, has helped in evaluating the complex pathogenetic mechanisms of different diseases from a broad perspective and has made substantial contributions [20,21]. In veterinary medicine, proteomic analysis of metabolic diseases such as ketosis [16], hypocalcemia [22], and fatty liver [23] in dairy cows has contributed valuable insights for the definition of new pathophysiological pathways and new diagnosis and treatment protocols for these diseases. The proteomic approach can contribute importantly to a broad and detailed understanding of the changes that occur at the organismal level associated with the increase in BHBA concentration in goats with pregnancy toxemia. Our aim was to evaluate the serum protein profiles of goats with SPT or CPT using proteomic techniques to determine the proteomic profiles of these animals and to identify the relevant pathophysiological mechanisms.

[11] Novel variants in KAT6B spectrum of disorders expand our knowledge of clinical manifestations and molecular mechanisms

• Authors: M. Yabumoto, Jessica Kianmahd, Meghna Singh, Maria F. Palafox, Angela Wei et al.
• Year: 2021
• Venue: Molecular Genetics & Genomic Medicine
• URL: https://www.semanticscholar.org/paper/3a47a1b1208ba7420900b090d3d7d712ed391719
• DOI: 10.1002/mgg3.1809
• PMID: 34519438
• PMCID: 8580094
• Citations: 12
• Influential citations: 2
• Summary: A range of features previously described for KAT6B‐related syndromes are identified, including concern for keratoconus, sensitivity to light or noise, recurring infections, and fractures in greater numbers than previously reported.
• Evidence snippets:
• Snippet 1 (score: 0.354) > Finally, as gene-centric models of disease have started to take hold, understanding the underlying functional mechanisms that are affected can help us elucidate the effect on molecular and cellular phenotypes that are regulated by KAT6B (Klein et al., 2019;Sheikh et al., 2012). We developed a model of KAT6B truncating variants in a human cell line to explore how these variants result in differential regulation of key transcripts. These types of approaches have been performed in a high throughput manner for tumor suppressor genes like BRCA1 (Findlay et al., 2018) and TP53 (Kotler et al., 2018) and can help identify key pathways that are dysregulated by KAT6B-related disorders and could be future targets for translational research. > Here, we analyze 20 clinical cases representing a KAT6B-related clinical spectrum across three domains: their genotype, phenotype, and experience with genetic counseling resources. Furthermore, we developed an in vitro model of KAT6B mutations using CRISPR technology to explore the effect of protein truncation on global transcriptional regulation. Here we demonstrate that the genes that drive core clinical phenotypes are enriched in our in vitro model system. Together, we show that our clinical observations parallel the transcriptional processes in our cell model systems which allow for a further understanding of the mechanisms underlying the KAT6Brelated clinical spectrum.

[12] WNT Signaling and Bone: Lessons From Skeletal Dysplasias and Disorders

• Authors: Yentl Huybrechts, G. Mortier, E. Boudin, W. Van Hul
• Year: 2020
• Venue: Frontiers in Endocrinology
• URL: https://www.semanticscholar.org/paper/00fd0aa090f258a34c6590bc3dee4b211ecb0929
• DOI: 10.3389/fendo.2020.00165
• PMID: 32328030
• PMCID: 7160326
• Citations: 95
• Summary: This review discusses the skeletal disorders that are included in the latest nosology of skeletal disorders and that are caused by genetic defects involving the Wingless and int-1 (WNT) signaling pathway.
• Evidence snippets:
• Snippet 1 (score: 0.352) > The identification of novel disease-causing genes for rare skeletal dysplasias accelerated significantly in the last decades, initially by positional cloning efforts and more recently by the availability of next-generation sequencing technology. This resulted in the identification of the disease-causing gene for 92% of the skeletal disorders (6). The increased knowledge on monogenic diseases resulted in a better understanding of the pathological mechanisms and highlighted which pathways regulate specific cellular processes. This information is also relevant for understanding more common multifactorial diseases. Furthermore, it has been shown that therapeutic targets which are based on genetic evidence from Mendelian traits as well as genome-wide association studies (GWASs) are more likely to be successful in clinical studies for multifactorial diseases (150). Here, we focused on skeletal dysplasias caused by mutations in genes that encode proteins that are directly involved in one of the WNT signaling pathways. As shown in Table 1, mutations in these genes can result in a variety of skeletal dysplasias, each with specific clinical features. The broad spectrum of clinical observations reflect the cellular and spatial functions of WNT signaling, some of them associated with embryonal development, others with bone mass and homeostasis in adult life. For example, the clinical features of RS and OMOD are similar which led to the hypothesis that all causative genes are involved in the WNT/PCP pathway which is previously shown to be important during limb development (Figure 2) (102). On the other hand, the influence of canonical WNT signaling on bone mass was highlighted by unraveling the underlying pathogenic mechanisms of disorders with a progressively increasing bone mass such as sclerosteosis, Van Buchem disease, and high bone mass phenotypes (osteosclerosis) (51,53,57,107,113). The genes causing these disorders, SOST, LRP4, LRP5, and LRP6, are all involved in the canonical WNT signaling pathway (Figure 3), and all mutations reported result in an increased canonical WNT signaling (Table 1).

[13] Structurally Abnormal Type II Collagen in a Severe Form of Kniest Dysplasia Caused by an Exon 24 Skipping Mutation*

• Authors: M. Weis, D. Wilkin, Hyon J. Kim, W. Wilcox, R. Lachman et al.
• Year: 1998
• Venue: The Journal of Biological Chemistry
• URL: https://www.semanticscholar.org/paper/f4ceef39beade5f86935d7f3541145bf37aaa9cb
• DOI: 10.1074/JBC.273.8.4761
• PMID: 9468540
• Citations: 45
• Influential citations: 1
• Summary: Results are reported that define the underlying genetic defect and consequent altered structure of assembled type II collagen in a neonatal lethal form of Kniest dysplasia and support a hypothesis that normal and short α-chains had combined to form heterotrimeric molecules in which the chains were in register in both directions from the deletion site.
• Evidence snippets:
• Snippet 1 (score: 0.352) > Type II collagen mutations have been identified in a phenotypic continuum of chondrodysplasias that range widely in clinical severity. They include achondrogenesis type II, hypochondrogenesis, spondyloepiphyseal dysplasia congenita, spondyloepimetaphyseal dysplasia, Kniest dysplasia, and Stickler syndrome. We report here results that define the underlying genetic defect and consequent altered structure of assembled type II collagen in a neonatal lethal form of Kniest dysplasia. Electrophoresis of a cyanogen bromide (CNBr) (CB) digest of sternal cartilage revealed an α1(II)CB11 peptide doublet and a slightly retarded mobility for all major CB peptides, which implied post-translational overmodification. Further peptide mapping and sequence analysis of CB11 revealed equal amounts of a normal α1(II) sequence and a chain lacking the 18 residues (361–378 of the triple helical domain) corresponding to exon 24. Sequence analysis of an amplified genomic DNA fragment identified a G to A transition in the +5 position of the splice donor consensus sequence of intron 24 in one allele. Cartilage matrix analysis showed that the short α1(II) chain was present in collagen molecules that had become cross-linked into fibrils. Trypsin digestion of the pepsin-extracted native type II collagen selectively cleaved the normal length α1(II) chains within the exon 24 domain. These findings support a hypothesis that normal and short α-chains had combined to form heterotrimeric molecules in which the chains were in register in both directions from the deletion site, accommodated effectively by a loop out of the normal chain exon 24 domain. Such an accommodation, with potential overall shortening of the helical domain and hence misalignment of intermolecular relationships within fibrils, offers a common molecular mechanism by which a group of different mutations might act to produce the Kniest phenotype.

[14] Clinical and Genetic Insights into Desbuquois Dysplasia: Review of 111 Case Reports

• Authors: Hubert Piwar, M. Ordak, Magdalena Bujalska-Zadrożny
• Year: 2024
• Venue: International Journal of Molecular Sciences
• URL: https://www.semanticscholar.org/paper/49abd91511392c535dc098d7cfc55c4096c58c72
• DOI: 10.3390/ijms25179700
• PMID: 39273648
• PMCID: 11395126
• Citations: 4
• Influential citations: 1
• Summary: The review highlights the phenotypic variations across Desbuquois dysplasia subtypes, particularly in facial characteristics, joint dislocations, and bone deformities and underscores the importance of early diagnosis and the potential for personalized therapeutic approaches.
• Evidence snippets:
• Snippet 1 (score: 0.349) > The use of supraglottic devices, like the CobraPLA, may provide a viable alternative for maintaining a secure airway. However, the success of such devices may vary, and backup plans, including the use of advanced intubation techniques, should be prepared [54]. > This review highlights the significant variability in genetic mutations associated with Desbuquois dysplasia and their impact on clinical phenotypes. The predominance of DBQD1 cases in the literature suggests that further studies should investigate whether this reflects a true higher prevalence or whether it is a consequence of diagnostic biases. Additionally, the observation of developmental delays in a significant proportion of patients underscores the importance of early diagnosis and intervention. Future research should focus on several key areas: firstly, further studies are needed to deepen our understanding of the correlation between specific mutations and the clinical manifestations of Desbuquois dysplasia, which could help to refine the diagnostic criteria and improve prognostic predictions. Secondly, investigating the pathogenic pathways involving CANT1 and other relevant genes in Desbuquois dysplasia, particularly in comparison with their roles in other conditions, such as cancers, could uncover new insights into the disease's underlying mechanisms and identify potential biomarkers for earlier diagnosis or predicting disease progression. Thirdly, given the phenotypic variability observed among patients, there is a need for personalized therapeutic strategies that are tailored to individual clinical profiles. Future research should explore the potential for developing targeted therapies, such as enzyme replacement or gene therapies, based on the molecular and genetic characteristics of each patient. Moreover, conducting longitudinal studies in patients with Desbuquois dysplasia would provide valuable data on disease progression, response to treatment, and long-term outcomes, helping to identify critical periods for intervention that might improve patient outcomes. Finally, the development and implementation of advanced molecular diagnostic techniques could facilitate an earlier and more accurate diagnosis of Desbuquois dysplasia, allowing for early intervention and potentially improving the quality of life and prognosis in affected individuals. While significant progress has been made in understanding Desbuquois dysplasia, ongoing research is essential to translate these findings into improved clinical care.

[15] 18O-assisted dynamic metabolomics for individualized diagnostics and treatment of human diseases

• Authors: E. Nemutlu, Song Zhang, N. Juranic, A. Terzic, S. Macura et al.
• Year: 2012
• Venue: Croatian Medical Journal
• URL: https://www.semanticscholar.org/paper/880f053c7f060db4b990e447d0a22c4b69372ddb
• DOI: 10.3325/cmj.2012.53.529
• PMID: 23275318
• PMCID: 3541579
• Citations: 28
• Summary: The potential use of dynamic phosphometabolomic platform for disease diagnostics currently under development at Mayo Clinic is described and discussed briefly.
• Evidence snippets:
• Snippet 1 (score: 0.348) > Living cells represent an integrated and interacting network of genes, transcripts, proteins, small signaling molecules, and metabolites that define cellular phenotype and function. Traditionally the focus of biomedical research was on individual genes, single protein targets, single metabolites, and metabolic or signaling pathways. This "molecular reductionist" paradigm was based on the assumption that identifying genetic variations and molecular components would lead to discovery of cures for human diseases. However, most of diseases are complex and multi-factorial and the disease phenotype is determined by the alterations of multiple genes, pathways, proteins and metabolites (at cellular, tissue, and organismal levels). Therefore, an integrated "omics" approach is more viable direction for uncovering alterations in metabolic networks, disease mechanisms, and mechanisms of drug effects. > Recent advent of large-scale metabolomics and fluxomic (metabolite dynamics and metabolic flux analysis) completed the "omics revolution" (Figure 1), where genomics, transcriptomics, proteomics, metabolomics, and fluxomics all together complement phenotype determination of living organism. Such integrated "omics" cascades provide a framework for advances in system and network biology, integrative physiology, and system medicine as well as system pharmacology and regenerative medicine. Noteworthy is the "reverse omic" approach or "metabolomicsinformed pharmacogenomics, " where discovery of specific metabolite changes have led to discovery of genetic alterations (2). Therefore, bringing new "omics" technologies to clinical practice will improve disease diagnostics and treatment by targeting drugs and procedures for each unique transcriptomic and metabolomic profiles.

[16] Deciphering cellular states of innate tumor drug responses

• Authors: Esther Graudens, V. Boulanger, Cindy Mollard, R. Mariage-Samson, Xavier Barlet et al.
• Year: 2006
• Venue: Genome Biology
• URL: https://www.semanticscholar.org/paper/c79e62f4751e287a9527444fdeae83162022d48a
• DOI: 10.1186/gb-2006-7-3-r19
• PMID: 16542501
• PMCID: 1557757
• Citations: 135
• Influential citations: 7
• Summary: Molecular interaction networks are described that provide a solid foundation on which to anchor working hypotheses about mechanisms underlying in vivo innate tumor drug responses, and represent a starting point from which by-pass chemotherapy schemes may be developed for critical therapeutic intervention in CRC patients.
• Evidence snippets:
• Snippet 1 (score: 0.347) > to TOP1 inhibitors [20,22]. > Our current understanding of mechanisms associated with drug resistance has been furthered by investigating drugresistant cellular models created by exposing a parental population (yeast, bacteria, mammalian cell lines) to increasing concentrations of a cytotoxic agent [23][24][25][26]. It has been difficult, however, to translate these insights into clinically meaningful improvements in cancer treatment, suggesting that in vitro unicellular models may not be applicable to the in vivo situation or represent the disease in its entirety. For instance, in CRC, TOP1 mutations that decrease the formation of DNA cleavage complexes were identified [27], but their implication in clinical resistance was not confirmed. > Since the introduction of molecular genetics methods in clinical oncology, examination of individual mRNA/protein expression levels of drug target molecules provided complementary indications on the mechanisms involved. Thus far, however, only a limited number of clinical studies of drug resistance have focused on individual candidate genes and these used clinical samples exclusively derived from patients that were already treated with drugs. In CRC, such gene-bygene molecular biology studies have highlighted only a partial list of candidate genes [28][29][30][31][32][33]; some of these genes were shown to be involved in mechanisms altering drug metabolite potency, others are known to participate in increase of drug efflux or decrease of drug toxicity, or to participate in inhibition of apoptosis (for an overview, see [32][33][34][35][36][37]). It is unclear at present whether these mechanisms play a causative role in clinical drug resistance, and no comprehensive analysis of entire drug resistance pathways has been conducted. > Pharmacogenetics and pharmacogenomics approaches have been initiated to study the relationship between individual variations and drug response rates [38,39]. Genetic polymorphisms of specific genes were found to be associated with clinical outcomes in patients treated through chemotherapy, and amplification of genes encoding drug targets or transporters was shown to alter the sensitivity of cancer cells to a particular chemotherapy [40,41]. Finally, loss of heterozygosity at specific regions of chromosomes was identified in specific carcinoma, although its consequence in treatment outcome remains

[17] Developing a Knowledge Graph Framework for Pharmacokinetic Natural Product-Drug Interactions

• Authors: Sanya Bathla Taneja, T. Callahan, M. Paine, S. Kane‐Gill, H. Kilicoglu et al.
• Year: 2022
• Venue: Journal of biomedical informatics
• URL: https://www.semanticscholar.org/paper/9c99c796c4ffb0f8db8956402b603dcc24bc96e7
• DOI: 10.1016/j.jbi.2023.104341
• PMID: 36933632
• Citations: 14
• Summary: NP-KG is the first KG to integrate biomedical ontologies with full texts of the scientific literature focused on natural products, and is demonstrated to identify known pharmacokinetic interactions between natural products and pharmaceutical drugs mediated by drug metabolizing enzymes and transporters.
• Evidence snippets:
• Snippet 1 (score: 0.347) > Entities from the OBO Foundry ontologies (diseases from Mondo Disease Ontology [25]; phenotypes from Human Phenotype Ontology [26]; anatomical entities from Uber Anatomy Ontology [27]; biological processes, cellular components, and molecular functions from Gene Ontology [28]; proteins from Human Protein Ontology [29]; pathways from Pathway Ontology [30]; chemicals from ChEBI ontology [22]; genes and variants from Sequence Ontology [31]; and cells from Cell Ontology [32] and Cell Line Ontology [33]) and linked data sources were integrated in the KG with the PheKnowLator workflow. > In addition to the ontologies and data sources originally included in the PheKnowLator workflow [34], we extended the workflow to include the Ontology of Adverse Events [35] and data from the following drug data sources in the ontology-grounded KG: > • Drug Interaction Knowledge Base (DIKB) (v2017) [36,37]: evidence of enzyme substrates and inhibition, including in vitro information, drug label statements, and results from randomized clinical trials. To simplify the knowledge representation, only the positive evidence present in DIKB was included in the KG. > • Drug Central database (v2017) [38]: in vitro evidence of enzyme inhibition, drug-transporter interactions, drug-bacteria interactions, and enzyme and transporter substrates. > • FDA Drug Interaction database (v2017) [39]: in vitro and clinical evidence of enzyme and transporter substrates and inhibitors. We included all data where the reported fold change in area under the receiver operating characteristic curve of the drug substrate for an enzyme or transporter is at least 2-fold in the presence of a purported inhibitor drug. This cut-off was chosen because it represents strong positive evidence of a clinically measurable pharmacokinetic mechanism (i.e., the primary drug clearance pathway involves a specific enzyme or transporter that can be inhibited by a drug to a clinically measurable extent). > The 2017 versions of the above databases were included to enable time-slicing in the KG. The timeslicing approach for KG evaluation splits the graph to predict chronologically later links.

[18] Recent advances in modelling of cerebellar ataxia using induced pluripotent stem cells

• Authors: M. M. Wong, L. Watson, Esther B. E. Becker
• Year: 2017
• Venue: Journal of neurology & neuromedicine
• URL: https://www.semanticscholar.org/paper/0d962652305116e383ab260b9e82d3a5ffe1722f
• DOI: 10.29245/2572.942X/2017/7.1134
• PMID: 28825058
• PMCID: 5558869
• Citations: 9
• Summary: This review focuses on recent breakthroughs in generating human iPSC-derived Purkinje cells and highlights the future challenges that will need to be addressed in order to fully exploit these models for the modelling of the molecular mechanisms underlying cerebellar ataxias and the development of effective therapeutics.
• Evidence snippets:
• Snippet 1 (score: 0.345) > dominant polyglutamine spinocerebellar ataxias (SCAs) are the most studied forms of ataxias. Despite significant clinical and genetic heterogeneity, emerging evidence points to the existence of common pathogenic mechanisms that may be shared by several genetically distinct forms of cerebellar ataxias (reviewed in5-8). However, it is still unclear how the proposed pathological pathways ultimately result in cerebellar dysfunction and degeneration, predominantly affecting Purkinje cells. > Understanding disease mechanisms is key to treating neurodegenerative disorders. The heterogeneous nature of the cerebellar ataxias combined with the unavailability of human brain tissue and the lack of reliable disease models have, however, hampered our understanding of the molecular disease mechanisms underlying cerebellar ataxias and thus, the development of effective therapies. Although mouse models of several cerebellar ataxias, including FRDA and SCAs, have provided valuable insights into the pathophysiology of these disorders (reviewed in9), many questions remain about the observed species differences in disease phenotypes and the effectiveness of potential drugs in clinical trials. > To help translate research from animal models into novel treatments for ataxia patients, it is essential to validate findings in the relevant affected human cell types, particularly in cerebellar Purkinje cells. The current obstacles might be overcome by exploiting recently developed human induced pluripotent stem cell (iPSC) technology and neuronal differentiation protocols.

[19] Signaling Pathways in Bone Development and Their Related Skeletal Dysplasia

• Authors: Alessandra Guasto, V. Cormier-Daire
• Year: 2021
• Venue: International Journal of Molecular Sciences
• URL: https://www.semanticscholar.org/paper/c5466b45e1a7e5aa8e7ad05c7d9287a9e84e9262
• DOI: 10.3390/ijms22094321
• PMID: 33919228
• PMCID: 8122623
• Citations: 51
• Summary: The principal signaling pathways involved in bone development and their associated skeletal dysplasia are reviewed and genotype–phenotype correlations have helped to elucidate their role in skeletogenesis.
• Evidence snippets:
• Snippet 1 (score: 0.344) > In this review, we discussed the main signaling pathways involved in bone development and how mutations in their components have been associated with SD. It is important to highlight that even if the signaling pathways have been discussed independently, there is a complex cross-talk among them at multiple levels. This, in association with the evidence that the mutation consequences depend on the specificity of the mutations and on their temporal and spatial mode of action, makes more difficult the understanding of the physiopathological mechanisms of these diseases. Moreover, these signaling pathways can be secondarily affected by alterations in other cellular processes, such as extracellular matrix regulation or metabolic processing. Indeed, several skeletal dysplasia, that we decided to omit in this review, have been associated with mutations in these processes. Fortunately, in the last decade, the development of new technologies, like whole exome and genome sequencing has accelerated the identification of skeletal dysplasia-causing mutations. On the other hand, the development of CRISPR-Cas9 technology and of several mouse models is helping the deciphering of the physiopathological mechanisms. Advanced genetic testing is also helping the diagnosis of skeletal dysplasia. The diagnosis and management of these pathologies have long been based on clinical feature and skeletal imaging. Today, these key techniques are increasingly combined with the genetic testing in order to obtain a more accurate and early diagnosis of SD. It also aids in prognosis and in counselling families regarding genetic recurrence risk and preconceptional reproductive planning [212][213][214]. These continuous discoveries will help to expand the genotype-phenotype correlation of SD and to develop new therapeutic strategies. Nowadays, few treatments are available for SD, but several clinical trials are ongoing to validate new drugs targeting specifically these pathways in achondroplasia or FOP for example, and highlighting the importance of multidisciplinary cross talks (from bed to bench side) [215].

Notes

• This provider combines search_papers_by_relevance with snippet_search.
• No synthesis or second-stage model call is performed.

Disorder

• Name: Kniest Dysplasia
• Category: Mendelian
• Existing deep-research providers: cyberian-codex, perplexity
• Existing evidence reference count in YAML: 21

Key Pathophysiology Nodes

• Type II Collagen Structural Abnormality
• Deep research literature mapping

Citation Inventory (for evidence mapping)

• DOI:10.1073/pnas.1300480110
• DOI:10.1126/sciadv.abg8583
• DOI:10.2214/ajr.123.4.805
• DOI:10.3892/mmr.2022.12615
• PMID:11680679
• PMID:11812423
• PMID:12954239
• PMID:15577070
• PMID:25592122
• PMID:3276736
• PMID:514691
• PMID:7700721
• PMID:7981752
• PMID:8484485
• PMID:8723084
• PMID:9524360

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Pathophysiology Research Template

Target Disease

• Disease Name: Kniest Dysplasia
• MONDO ID: (if available)
• Category: Mendelian

Research Objectives

Please provide a comprehensive research report on the pathophysiology of Kniest Dysplasia. Focus on the molecular and cellular mechanisms underlying disease progression.

Required Information

1. Core Pathophysiology

• What are the primary pathophysiological mechanisms?
• What molecular pathways are dysregulated?
• What cellular processes are affected?

2. Key Molecular Players

• Genes/Proteins: Which genes are causally involved or implicated?
• Chemical Entities: What metabolites, drugs, or small molecules are relevant?
• Cell Types: Which cell types are primarily affected?
• Anatomical Locations: Which tissues/organs are involved?

3. Biological Processes (for GO annotation)

• What biological processes (GO terms) are disrupted?
• Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

4. Cellular Components

• Where in the cell do key processes occur?
• Consider: organelles, membrane compartments, extracellular space, etc.

5. Disease Progression

• What is the sequence of events from initial trigger to clinical manifestation?
• Are there distinct stages or phases?

6. Phenotypic Manifestations

• What are the key clinical phenotypes?
• How do they relate to the underlying mechanisms?

Citation Requirements

• Cite primary literature (PMID preferred) for all mechanistic claims
• Prioritize recent reviews and landmark papers
• Include direct quotes where possible to support key statements

Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with: - Pathophysiology description - Gene/protein annotations with ontology terms (HGNC, GO) - Phenotype associations (HP terms) - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Evidence items with PMIDs

Comprehensive Pathophysiology Research Report: Kniest Dysplasia

0) Disease identifiers and definition

• Disease: Kniest dysplasia (a type II collagenopathy, Mendelian skeletal dysplasia). (sergouniotis2015ophthalmicandmolecular pages 1-2, niida2023streamlininggeneticdiagnosis pages 1-2)
• MONDO: MONDO:0007987 (OpenTargets disease node for Kniest dysplasia). ()
• OMIM: Kniest dysplasia #156550; differential-diagnosis group includes other COL2A1-related disorders (e.g., SEDC #183900, SEMD Strudwick #184250, etc.). (sergouniotis2015ophthalmicandmolecular pages 1-2, weis1998structurallyabnormaltype pages 1-2)
• Causal gene: COL2A1 (collagen type II alpha 1 chain; gene record cited as MIM #108300 in mutation-review literature). (barathouari2016mutationupdatefor pages 1-2)
• Inheritance: typically autosomal dominant, with frequent de novo occurrence in case series. (sergouniotis2015ophthalmicandmolecular pages 1-2)

1) Core pathophysiology (molecular and cellular mechanisms)

Kniest dysplasia is driven by structural defects in type II collagen (procollagen-II) that perturb collagen biosynthesis, folding, secretion, and extracellular matrix (ECM) assembly in cartilage and other COL2A1-expressing tissues.

1.1 Primary molecular lesion: disrupted collagen II triple helix (dominant-negative)

Type II collagen’s triple helix requires a Gly-X-Y repeating motif. Many Kniest-causing variants are in-frame deletions or splice-altering variants that preserve the reading frame but interrupt the triple helix and produce shortened α1(II) chains that co-assemble with normal chains (dominant-negative effect).

• Exon 12 cryptic splice donor activation: Chen et al. (1996) showed that a C→T transition introduced a GT dinucleotide within exon 12, producing alternatively spliced COL2A1 mRNA lacking 21 nucleotides; this causes loss of residues Ala102–Lys108 and interrupts the Gly-X-Y repeats required for helix formation. The authors conclude: “This study highlights the importance of dominant negative mutations of COL2A1 in producing Kniest dysplasia.” (chen1996alternativesplicingof pages 1-2)

• Exon 15 skipping: Fernandes et al. (1998) identified a splice donor mutation causing an in-frame deletion (15 amino acids encoded by exon 15) in ~25% of α1(II) chains in cartilage, and concluded coassembly: “This is best explained by the coassembly of normal and truncated α1(II) chains into heterotrimers.” (fernandes1998incorporationofstructurally pages 1-2)

• Exon 24 skipping: Weis et al. (1998) described a splice donor mutation causing loss of 18 residues corresponding to exon 24. Their analysis supports incorporation of shortened chains into fibrils and a “loop-out” accommodation model for heterotrimers. (weis1998structurallyabnormaltype pages 1-2)

1.2 Post-translational overmodification and defective fibrillogenesis

Abnormal chains can undergo post-translational overmodification (e.g., delayed folding allowing excess hydroxylation/glycosylation) and yield fibrils that are structurally abnormal. - In exon 12-related disease, Kniest cartilage contained reduced pepsin-solubilized type II collagen with “overmodified α1(II) chains” with overmodifications extending to the carboxyl terminus. (chen1996alternativesplicingof pages 1-2) - Weis et al. (1998) also inferred post-translational overmodification from retarded peptide mobility. (weis1998structurallyabnormaltype pages 1-2)

1.3 Intracellular retention (ER storage) and organelle pathology

A recurring cellular hallmark is intracellular retention of type II procollagen and dilated rough endoplasmic reticulum (rER) in chondrocytes. - Fernandes et al. (1998) summarizes prior ultrastructural observations: “the chondrocytes contain pronounced dilated cisternae of the rough endoplasmic reticulum … filled with material that stains positively for type II procollagen.” (fernandes1998incorporationofstructurally pages 1-2) - Broader integrated evidence for COL2A1 collagenopathies indicates mutant collagen can be retained with distended/dilated rER and Golgi and cause sparse/abnormal ECM fibrils. (zhang2020integratedanalysisof pages 14-18)

1.4 ECM-level failure: “Swiss cheese” cartilage and impaired mechanical integrity

At the tissue level, defective collagen II incorporation and fibril disorganization yields the characteristic diagnostic matrix phenotype. - Weis et al. (1998) describes cartilage morphology termed “Swiss cheese” cartilage, with sparse, thin collagen fibrils in the perilacunar region and thickened fibrils peripherally. (weis1998structurallyabnormaltype pages 1-2) - Fernandes et al. (1998) similarly notes a crumbly cartilage consistency and diagnostic Swiss-cheese appearance, supporting compromised mechanical strength. (fernandes1998incorporationofstructurally pages 1-2)

1.5 Dysregulated pathways: ER stress / UPR is context- and mutation-dependent

Older collagenopathy literature and integrated analyses support that some mutant COL2A1 alleles can engage ER stress/UPR cascades; however, recent work suggests some ER storage defects do not trigger canonical UPR. - A COL2A1 mouse model (p.Gly1170Ser) is cited as activating an “ER stress–unfolding protein response–apoptosis cascade” in some type II collagenopathies (referenced in integrated review). (zhang2020integratedanalysisof pages 24-26) - 2023–2024 major mechanistic development (proteostasis nuance): iPSC-derived human cartilage models show that mutant procollagen-II can accumulate in the ER without robust UPR activation: - Yammine et al. (bioRxiv preprint, Oct 2024 DOI; posted 2024) report “ER procollagen storage defect without coupled unfolded protein response” for Gly1170Ser in human iPSC-derived cartilage. (yammine2023erprocollagenstorage pages 1-5) - Yammine et al. (bioRxiv preprint, Nov 2024 DOI; posted later) show Arg719Cys causes ER distention and a defective matrix, but mutant collagen “was not detectably recognized by the ER proteostasis network” and fails to activate quality control responses including UPR—framed as failed cellular surveillance. (yammine2024humancartilagemodel pages 1-4)

2) Key molecular players

2.1 Genes/proteins

• COL2A1 (HGNC:2208) is the primary causal gene. (barathouari2016mutationupdatefor pages 1-2)
• The pathogenic mechanism is typically dominant-negative, especially for in-frame exon skipping/deletions that produce mutant chains incorporated into fibrils (heterotrimers). (chen1996alternativesplicingof pages 1-2, fernandes1998incorporationofstructurally pages 1-2, weis1998structurallyabnormaltype pages 1-2)
• Recent functional work indicates mutant collagen can perturb ECM networks beyond collagen fibrils; e.g., p.Gly444Ser showed intracellular collagen-II accumulation and a disorganized fibronectin network in ECM assays. (marchionni2023clinicalandfunctional pages 1-2)

Variant/statistics context (recently cited): - A 2016 mutation-update review reported “Over 700 patients… harboring 415 different mutations” in COL2A1 from LOVD plus curation. (barathouari2016mutationupdatefor pages 1-2) - A 2023 functional paper states “Over 600 pathogenic variants” have been described in COL2A1. (marchionni2023clinicalandfunctional pages 1-2) - A 2020 integrated analysis compiled 663 probands and 460 distinct COL2A1 mutations across 21 disorders (not Kniest-specific but provides spectrum context). (zhang2020integratedanalysisof pages 1-6)

2.2 Chemical entities (metabolites/drugs/small molecules)

No disease-modifying small molecule is established for Kniest dysplasia in the retrieved evidence. Current management is largely supportive and surgical. (niida2023streamlininggeneticdiagnosis pages 1-2, yammine2024humancartilagemodel pages 1-4) - Orthopedic end-stage interventions (joint replacement) are frequently required for severe early osteoarthritis COL2A1 phenotypes; Arg719Cys families are described as often needing multiple joint replacements. (yammine2024humancartilagemodel pages 1-4)

2.3 Cell types

• Chondrocytes (CL:0000138) are the primary affected cell type, producing type II collagen and showing ER dilation, altered secretion, and abnormal ECM deposition. (fernandes1998incorporationofstructurally pages 1-2, zhang2020integratedanalysisof pages 14-18)

2.4 Anatomical locations (tissues/organs)

Type II collagen is a major ECM component in: - Hyaline cartilage / growth plate cartilage (skeletal dysplasia core). (fernandes1998incorporationofstructurally pages 1-2, weis1998structurallyabnormaltype pages 1-2) - Vitreous body (ocular manifestations). (sergouniotis2015ophthalmicandmolecular pages 1-2) - Inner ear (hearing impairment). (sergouniotis2015ophthalmicandmolecular pages 1-2)

3) Biological processes disrupted (GO-oriented)

The evidence supports disruption of: - Collagen fibril organization / extracellular matrix assembly (mutant collagen incorporated into fibrils; abnormal fibril alignment and density; Swiss-cheese cartilage). (fernandes1998incorporationofstructurally pages 1-2, weis1998structurallyabnormaltype pages 1-2) - Protein folding and quality control in the ER (ER storage; mutation-specific engagement or failure to engage proteostasis/UPR). (yammine2023erprocollagenstorage pages 1-5, yammine2024humancartilagemodel pages 1-4) - Collagen biosynthetic processing and trafficking (ER→Golgi) (intracellular accumulation; Golgi vesicle localization in functional assays). (marchionni2023clinicalandfunctional pages 1-2)

4) Cellular components (where processes occur)

• Rough endoplasmic reticulum (rER): pronounced dilation and storage of retained procollagen-II in chondrocytes. (fernandes1998incorporationofstructurally pages 1-2)
• Golgi-associated vesicles/secretory pathway: implicated in intracellular localization of collagen-II in recent functional assays. (marchionni2023clinicalandfunctional pages 1-2)
• Extracellular space / cartilage ECM: deposition of defective type II collagen network and disorganized fibrils. (weis1998structurallyabnormaltype pages 1-2, fernandes1998incorporationofstructurally pages 1-2)

5) Disease progression model (sequence of events)

1. Heterozygous pathogenic COL2A1 variant (often splice-altering or small in-frame deletion) produces a mutant α1(II) chain. (chen1996alternativesplicingof pages 1-2, fernandes1998incorporationofstructurally pages 1-2, weis1998structurallyabnormaltype pages 1-2)
2. Defective triple-helix folding and/or delayed folding leads to overmodification and a mixture of normal and shortened chains assembling into heterotrimers (dominant-negative). (chen1996alternativesplicingof pages 1-2, fernandes1998incorporationofstructurally pages 1-2, weis1998structurallyabnormaltype pages 1-2)
3. Intracellular retention of mutant procollagen-II causes rER distention (ER storage phenotype) in chondrocytes; depending on variant class, ER quality control may be activated or may fail to recognize the defect. (fernandes1998incorporationofstructurally pages 1-2, yammine2023erprocollagenstorage pages 1-5, yammine2024humancartilagemodel pages 1-4)
4. Secretion and deposition of malformed collagen and/or quantitative deficiency of a functional collagen network yields a sparse, mechanically weak ECM (“Swiss cheese” cartilage). (weis1998structurallyabnormaltype pages 1-2, fernandes1998incorporationofstructurally pages 1-2)
5. Tissue and developmental consequences: impaired endochondral ossification and skeletal growth; progressive joint abnormalities and secondary degenerative changes; extra-skeletal manifestations in vitreous and inner ear due to shared collagen dependence. (sergouniotis2015ophthalmicandmolecular pages 1-2, fernandes1998incorporationofstructurally pages 1-2)

6) Phenotypic manifestations (clinical features mapped to mechanisms)

Kniest dysplasia is multisystemic because COL2A1 is critical to cartilage and vitreous ECM.

Skeletal - Disproportionate short stature / short-trunk dwarfism with kyphoscoliosis, enlarged joints and restricted mobility. (sergouniotis2015ophthalmicandmolecular pages 1-2, fernandes1998incorporationofstructurally pages 1-2)

Ocular - High myopia and abnormal vitreous; high risk of retinal detachment. In an 8-person series, 6/7 tested were high myopes, 7/7 had abnormal vitreous, and one had bilateral retinal detachments in his twenties. (sergouniotis2015ophthalmicandmolecular pages 1-2)

Auditory - Hearing impairment is common; in the same series 6/7 had significant hearing impairment. (sergouniotis2015ophthalmicandmolecular pages 1-2)

Craniofacial / orofacial - Cleft palate and midface features; in the series 5/7 had clefting abnormalities. (sergouniotis2015ophthalmicandmolecular pages 1-2)

Airway - Airway cartilage involvement (e.g., tracheomalacia) and neonatal respiratory compromise is reported in case-based literature, consistent with cartilage matrix fragility. (gilbertbarnes1996kniestdysplasiaradiologic pages 1-2, jhamb2019orthodontictreatmentin pages 1-2)

7) Recent developments and latest research (2023–2024 emphasis)

7.1 Functional genomics and cell biology advances

• COL2A1 p.Gly444Ser functional characterization (Dec 2023): fibroblasts and in vitro chondrocyte differentiation demonstrated intracellular collagen-II accumulation, Golgi vesicle localization, and ECM network disorganization, supporting defective processing and fibril assembly. (marchionni2023clinicalandfunctional pages 1-2)
• Human iPSC-derived cartilage models (2024 preprints): mechanistically separate “ER storage” from canonical UPR activation and emphasize mutation-specific proteostasis engagement; these platforms are positioned for therapeutic discovery targeting collagen folding and quality control. (yammine2023erprocollagenstorage pages 1-5, yammine2024humancartilagemodel pages 1-4)

7.2 Diagnostics and real-world implementation

• Very long amplicon sequencing (vLAS; Dec 2023): long-range PCR + short-read NGS to cover large genes like COL2A1 (54 exons; ~31.5 kb) as an implementable diagnostic workflow for type II collagenopathies. (niida2023streamlininggeneticdiagnosis pages 1-2)

8) Expert opinions / authoritative synthesis

• Mutation-update and spectrum papers emphasize that early diagnosis is critical for appropriate care and genetic counseling, and that COL2A1 mutation classes show broad phenotypic diversity. (barathouari2016mutationupdatefor pages 1-2, niida2023streamlininggeneticdiagnosis pages 1-2)
• Ophthalmology experts recommend regular ophthalmologic surveillance because ocular morbidity is substantial and resembles Stickler-like vitreoretinal risk. (sergouniotis2015ophthalmicandmolecular pages 1-2)

9) Statistics and data highlights (from retrieved sources)

• Adult height expectation: 100–140 cm (reported in Kniest dysplasia clinical context). (sergouniotis2015ophthalmicandmolecular pages 1-2)
• Case series counts: 8 unrelated individuals in a molecularly confirmed ophthalmology series. (sergouniotis2015ophthalmicandmolecular pages 1-2)
• Ocular frequencies in that series: high myopia 6/7; abnormal vitreous 7/7; retinal detachment reported in 1 case (bilateral, in 20s). (sergouniotis2015ophthalmicandmolecular pages 1-2)
• Hearing impairment frequency: 6/7 in the same series. (sergouniotis2015ophthalmicandmolecular pages 1-2)
• Clefting frequency: 5/7 in the same series. (sergouniotis2015ophthalmicandmolecular pages 1-2)
• Variant/patient database scale: >700 patients and 415 different COL2A1 mutations recorded in a curated LOVD-based review (2016). (barathouari2016mutationupdatefor pages 1-2)

10) Knowledge-base structured annotations (ontology-ready)

The following structured table provides a starter set of ontology mappings and evidence items.

Table: A structured knowledge-base table mapping the molecular, cellular, and anatomical components of Kniest dysplasia to corresponding ontologies, phenotypes, and recent literature.

11) Key visual evidence (figures/tables)

Weis et al. (1998) provides key primary visual evidence supporting exon-skipping and cartilage pathology: - CB peptide gel showing α1(II)CB11 doublet (mutant + normal collagen peptides). (weis1998structurallyabnormaltype media 7bc63542) - Histology/EM demonstrating “Swiss cheese” cartilage morphology. (weis1998structurallyabnormaltype media 52912b9b) - RT-PCR confirming exon 24 skipping at the transcript level. (weis1998structurallyabnormaltype media b9b46098)

12) Evidence items list (PMID-focused; limitations)

The currently retrieved full texts and excerpts include DOIs and URLs but often do not display PMIDs in the captured text snippets. For completeness, PMIDs should be programmatically resolved from the DOIs for key mechanistic primary papers (e.g., Weis 1998 JBC; Fernandes 1998 Arch Biochem Biophys; Chen 1996 J Orthop Res; Sergouniotis 2015 Eye). Within this run, only PubMed IDs were explicitly returned by OpenTargets for COL2A1–Kniest evidence (e.g., 9091360; 10406661; 15895462; 7874117; 32867104), but the underlying statements from those specific PMIDs were not retrievable as full texts here. ()

URLs and publication dates (selected key sources)

• Marchionni et al., Dec 2023, Bone Reports: https://doi.org/10.1016/j.bonr.2023.101728 (marchionni2023clinicalandfunctional pages 1-2)
• Niida et al., Dec 13, 2023, Cureus: https://doi.org/10.7759/cureus.50482 (niida2023streamlininggeneticdiagnosis pages 1-2)
• Yammine et al., Oct 2024 (bioRxiv DOI), ER storage without UPR: https://doi.org/10.1101/2023.10.19.562780 (yammine2023erprocollagenstorage pages 1-5)
• Yammine et al., Nov 2024 (bioRxiv DOI), Arg719Cys cellular surveillance failure: https://doi.org/10.1101/2024.11.07.622468 (yammine2024humancartilagemodel pages 1-4)
• Sergouniotis et al., Jan 2015, Eye: https://doi.org/10.1038/eye.2014.334 (sergouniotis2015ophthalmicandmolecular pages 1-2)
• Weis et al., Feb 1998, J Biol Chem: https://doi.org/10.1074/jbc.273.8.4761 (weis1998structurallyabnormaltype pages 1-2)
• Fernandes et al., Jul 1998, Arch Biochem Biophys: https://doi.org/10.1006/abbi.1998.0745 (fernandes1998incorporationofstructurally pages 1-2)
• Chen et al., Sep 1996, J Orthop Res: https://doi.org/10.1002/jor.1100140506 (chen1996alternativesplicingof pages 1-2)

References

1. (sergouniotis2015ophthalmicandmolecular pages 1-2): P. Sergouniotis, G. Fincham, A. McNinch, Corinne M. Spickett, A. Poulson, A. Richards, and M. Snead. Ophthalmic and molecular genetic findings in kniest dysplasia. Eye, 29:475-482, Jan 2015. URL: https://doi.org/10.1038/eye.2014.334, doi:10.1038/eye.2014.334. This article has 26 citations and is from a peer-reviewed journal.

2. (niida2023streamlininggeneticdiagnosis pages 1-2): Yo Niida, Sumihito Togi, and Hiroki Ura. Streamlining genetic diagnosis with long-range polymerase chain reaction (pcr)-based next-generation sequencing for type i and type ii collagenopathies. Cureus, Dec 2023. URL: https://doi.org/10.7759/cureus.50482, doi:10.7759/cureus.50482. This article has 3 citations.

3. (weis1998structurallyabnormaltype pages 1-2): Mary Ann Weis, Douglas J. Wilkin, Hyon J. Kim, William R. Wilcox, Ralph S. Lachman, David L. Rimoin, Daniel H. Cohn, and David R. Eyre. Structurally abnormal type ii collagen in a severe form of kniest dysplasia caused by an exon 24 skipping mutation*. The Journal of Biological Chemistry, 273:4761-4768, Feb 1998. URL: https://doi.org/10.1074/jbc.273.8.4761, doi:10.1074/jbc.273.8.4761. This article has 59 citations.

4. (barathouari2016mutationupdatefor pages 1-2): Mouna Barat-Houari, Guillaume Sarrabay, Vincent Gatinois, Aurélie Fabre, Bruno Dumont, David Genevieve, and Isabelle Touitou. Mutation update for col2a1 gene variants associated with type ii collagenopathies. Human Mutation, 37:7-15, Jan 2016. URL: https://doi.org/10.1002/humu.22915, doi:10.1002/humu.22915. This article has 171 citations and is from a domain leading peer-reviewed journal.

5. (chen1996alternativesplicingof pages 1-2): Luping Chen, Winnie Yang, and William G. Cole. Alternative splicing of exon 12 of the col2a1 gene interrupts the triple helix of type‐ii collagen in the kniest form of spondyloepiphyseal dysplasia. Journal of Orthopaedic Research, 14:712-721, Sep 1996. URL: https://doi.org/10.1002/jor.1100140506, doi:10.1002/jor.1100140506. This article has 20 citations and is from a domain leading peer-reviewed journal.

6. (fernandes1998incorporationofstructurally pages 1-2): Russell J. Fernandes, D. Wilkin, D. Wilkin, MaryAnn Weis, William R. Wilcox, William R. Wilcox, Daniel H. Cohn, Daniel H. Cohn, D. Rimoin, D. Rimoin, and D. Eyre. Incorporation of structurally defective type ii collagen into cartilage matrix in kniest chondrodysplasia. Archives of biochemistry and biophysics, 355 2:282-90, Jul 1998. URL: https://doi.org/10.1006/abbi.1998.0745, doi:10.1006/abbi.1998.0745. This article has 49 citations and is from a peer-reviewed journal.

7. (zhang2020integratedanalysisof pages 14-18): Boyan Zhang, Yue Zhang, Naichao Wu, Jianing Li, He Liu, and Jincheng Wang. Integrated analysis of col2a1 variant data and classification of type ii collagenopathies. Clinical Genetics, 97:383-395, Dec 2020. URL: https://doi.org/10.1111/cge.13680, doi:10.1111/cge.13680. This article has 58 citations and is from a peer-reviewed journal.

8. (zhang2020integratedanalysisof pages 24-26): Boyan Zhang, Yue Zhang, Naichao Wu, Jianing Li, He Liu, and Jincheng Wang. Integrated analysis of col2a1 variant data and classification of type ii collagenopathies. Clinical Genetics, 97:383-395, Dec 2020. URL: https://doi.org/10.1111/cge.13680, doi:10.1111/cge.13680. This article has 58 citations and is from a peer-reviewed journal.

9. (yammine2023erprocollagenstorage pages 1-5): Kathryn M. Yammine, Sophia Mirda Abularach, Seo-yeon Kim, Agata A. Bikovtseva, Jinia Lilianty, Vincent L. Butty, Richard P. Schiavoni, John F. Bateman, Shireen R. Lamandé, and Matthew D. Shoulders. Er procollagen storage defect without coupled unfolded protein response drives precocious arthritis. BioRxiv, Oct 2024. URL: https://doi.org/10.1101/2023.10.19.562780, doi:10.1101/2023.10.19.562780. This article has 5 citations.

10. (yammine2024humancartilagemodel pages 1-4): Kathryn M. Yammine, Sophia Mirda Abularach, Michael Xiong, Seo-yeon Kim, Agata A. Bikovtseva, Vincent L. Butty, Richard P. Schiavoni, John F. Bateman, Shireen R. Lamandé, and Matthew D. Shoulders. Human cartilage model of the precocious osteoarthritis-inducingcol2a1p.arg719cys reveals pathology-driving matrix defects and a failure of the er proteostasis network to recognize the defective procollagen-ii. BioRxiv, Nov 2024. URL: https://doi.org/10.1101/2024.11.07.622468, doi:10.1101/2024.11.07.622468. This article has 1 citations.

11. (marchionni2023clinicalandfunctional pages 1-2): Enrica Marchionni, Maria Rosaria D'Apice, Viviana Lupo, Giovanna Lattanzi, Elisabetta Mattioli, Gina Lisignoli, Elena Gabusi, Gerardo Pepe, Manuela Helmer Citterich, Elena Campione, Anna Maria Nardone, Paola Spitalieri, Noemi Pucci, Dario Cocciadiferro, Eliseo Picchi, Francesco Garaci, Antonio Novelli, and Giuseppe Novelli. Clinical and functional characterization of col2a1 p.gly444ser variant: from a fetal phenotype to a previously undisclosed postnatal phenotype. Bone Reports, 19:101728, Dec 2023. URL: https://doi.org/10.1016/j.bonr.2023.101728, doi:10.1016/j.bonr.2023.101728. This article has 1 citations and is from a peer-reviewed journal.

12. (zhang2020integratedanalysisof pages 1-6): Boyan Zhang, Yue Zhang, Naichao Wu, Jianing Li, He Liu, and Jincheng Wang. Integrated analysis of col2a1 variant data and classification of type ii collagenopathies. Clinical Genetics, 97:383-395, Dec 2020. URL: https://doi.org/10.1111/cge.13680, doi:10.1111/cge.13680. This article has 58 citations and is from a peer-reviewed journal.

13. (gilbertbarnes1996kniestdysplasiaradiologic pages 1-2): Enid Gilbert-Barnes, Leonard O. Langer, John M. Opitz, Renata Laxova, and Cirilo Sotelo-Arila. Kniest dysplasia: radiologic, histopathological, and scanning electronmicroscopic findings. American journal of medical genetics, 63 1:34-45, May 1996. URL: https://doi.org/10.1002/(sici)1096-8628(19960503)63:1<34::aid-ajmg9>3.0.co;2-s, doi:10.1002/(sici)1096-8628(19960503)63:1<34::aid-ajmg9>3.0.co;2-s. This article has 52 citations.

14. (jhamb2019orthodontictreatmentin pages 1-2): Tania Jhamb, Hayat Masood, Jeffrey Arigo, and P. Emile Rossouw. Orthodontic treatment in a patient with kniest dysplasia: a case study and review of literature. The Cleft Palate-Craniofacial Journal, 56:1393-1403, Jun 2019. URL: https://doi.org/10.1177/1055665619854617, doi:10.1177/1055665619854617. This article has 5 citations.

15. (kaissi2022distinctiveskeletalphenotype pages 1-3): Ali Al Kaissi. Distinctive skeletal phenotype in patients with kniest dysplasia. Journal of Orthopaedic Science and Research, pages 1-10, Dec 2022. URL: https://doi.org/10.46889/josr.2022.3306, doi:10.46889/josr.2022.3306. This article has 0 citations.

16. (kaissi2022distinctiveskeletalphenotype pages 3-7): Ali Al Kaissi. Distinctive skeletal phenotype in patients with kniest dysplasia. Journal of Orthopaedic Science and Research, pages 1-10, Dec 2022. URL: https://doi.org/10.46889/josr.2022.3306, doi:10.46889/josr.2022.3306. This article has 0 citations.

17. (weis1998structurallyabnormaltype media 7bc63542): Mary Ann Weis, Douglas J. Wilkin, Hyon J. Kim, William R. Wilcox, Ralph S. Lachman, David L. Rimoin, Daniel H. Cohn, and David R. Eyre. Structurally abnormal type ii collagen in a severe form of kniest dysplasia caused by an exon 24 skipping mutation*. The Journal of Biological Chemistry, 273:4761-4768, Feb 1998. URL: https://doi.org/10.1074/jbc.273.8.4761, doi:10.1074/jbc.273.8.4761. This article has 59 citations.

18. (weis1998structurallyabnormaltype media 52912b9b): Mary Ann Weis, Douglas J. Wilkin, Hyon J. Kim, William R. Wilcox, Ralph S. Lachman, David L. Rimoin, Daniel H. Cohn, and David R. Eyre. Structurally abnormal type ii collagen in a severe form of kniest dysplasia caused by an exon 24 skipping mutation*. The Journal of Biological Chemistry, 273:4761-4768, Feb 1998. URL: https://doi.org/10.1074/jbc.273.8.4761, doi:10.1074/jbc.273.8.4761. This article has 59 citations.

19. (weis1998structurallyabnormaltype media b9b46098): Mary Ann Weis, Douglas J. Wilkin, Hyon J. Kim, William R. Wilcox, Ralph S. Lachman, David L. Rimoin, Daniel H. Cohn, and David R. Eyre. Structurally abnormal type ii collagen in a severe form of kniest dysplasia caused by an exon 24 skipping mutation*. The Journal of Biological Chemistry, 273:4761-4768, Feb 1998. URL: https://doi.org/10.1074/jbc.273.8.4761, doi:10.1074/jbc.273.8.4761. This article has 59 citations.

Kniest Dysplasia: Comprehensive Analysis of Pathophysiological Mechanisms and Disease Mechanisms

Kniest dysplasia represents a severe skeletal dysplasia affecting approximately one in one million births, caused by mutations in the COL2A1 gene encoding type II collagen[1][3]. This rare autosomal dominant condition manifests as short-limbed dwarfism characterized by distinctive pathological features including the pathognomonic "Swiss cheese" appearance of cartilage matrix due to hundreds of small holes in bone cartilage, severe joint stiffness and swelling, craniofacial anomalies, and significant vision and hearing impairment[1][2][24]. The disease represents one of multiple type II collagenopathies that collectively demonstrate the critical importance of proper type II collagen structure and function for normal skeletal development and tissue homeostasis. Understanding the pathophysiological mechanisms underlying Kniest dysplasia requires comprehensive analysis of how mutations in COL2A1 disrupt normal collagen synthesis, fibril assembly, and cellular responses during endochondral ossification, ultimately leading to the characteristic skeletal deformities and systemic complications observed in affected individuals.

Molecular Basis and Genetic Architecture of Kniest Dysplasia

The COL2A1 Gene and Type II Collagen Structure

The COL2A1 gene located on chromosome 12q13.11-q13.20 encodes the alpha-1(II) chain, which serves as the basic component of type II collagen[3][7]. This gene comprises exons that collectively code for a polypeptide of 1060 amino acid residues containing a large uninterrupted triple-helical region flanked by relatively short, non-helical telopeptides consisting of 19 amino acid residues in the N-telopeptide and 27 amino acid residues in the C-telopeptide[37]. Type II collagen serves critical structural and functional roles throughout the body, being found primarily in hyaline cartilage of the developing skeleton, growth plates at the ends of long bones, and in specialized tissues including the vitreous of the eye and the nucleus pulposus of intervertebral discs[3][7]. The triple-helical structure of type II collagen is stabilized through hydrogen bonds and cross-linkages at telopeptide regions between adjacent collagen molecules, forming collagen fibrils that provide the mechanical strength and structural integrity essential for normal skeletal development and cartilage function[8].

Mutation Types and Molecular Pathology

Kniest dysplasia results from heterozygous mutations in the COL2A1 gene, with the majority of cases representing new (de novo) mutations occurring during gamete formation in an unaffected parent or during early embryonic development[3][45]. The disease follows an autosomal dominant inheritance pattern, meaning that a single mutated copy of the gene in each cell is sufficient to cause the disorder; if an affected parent has Kniest dysplasia, each child has a 50 percent chance of inheriting the condition[1][3][24]. Many of the variants that cause Kniest dysplasia involve deletions of one or more DNA nucleotides in the COL2A1 gene, with mutations spanning exons 12 through 24 being particularly associated with the Kniest phenotype[33][37]. Small deletions in the type II collagen triple helix, in-frame deletions, and splice site mutations represent common molecular mechanisms, with recent characterization of novel splice mutations demonstrating both out-of-frame transcripts and in-frame deletions[14]. For instance, the c.1266+2T>A mutation identified in a patient with Kniest dysplasia caused aberrant splicing with intron 20 retention producing an out-of-frame transcript with a premature stop codon, while the short fragment resulted from exon 20 skipping, creating an in-frame deletion[14].

These mutations lead to the production of abnormal alpha-1(II) chains that fail to maintain proper triple-helical configuration[3][40]. The abnormal chains then associate with normal alpha-1(II) chains to form a mixed population of type II collagen molecules, resulting in a dominant-negative effect where the presence of misfolded collagen molecules disrupts the assembly of otherwise normal collagen fibrils[40]. The lack of functional type II collagen directly interferes with the development of bones and other connective tissues, as type II collagen is essential for normal growth and development of these structures[3].

Pathophysiology of Type II Collagen Synthesis and Fibril Assembly

Normal Type II Collagen Processing and Triple Helix Formation

Under normal circumstances, three alpha-1(II) chains synthesized in the rough endoplasmic reticulum form a procollagen molecule through a precisely coordinated assembly process[7]. The peptide bonds in the collagen chain are in the trans conformation, with three hydrogen bonds formed within each amino acid triplet according to the characteristic collagen repeat of Gly-X-Y, where glycine occupies every third position and the Y position is frequently occupied by hydroxyproline[11]. This critical primary structure is maintained through the stabilizing effects of proline and hydroxyproline residues, with hydroxyproline in the Yaa position (Y position of the Gly-X-Y repeat) stabilizing the triple helix through stereoelectronic effects[11]. Once procollagen molecules are synthesized and processed by enzymes within the cell, they exit the endoplasmic reticulum and are modified in the Golgi apparatus. The processed collagen molecules then arrange themselves into long, thin fibrils that attach to one another through cross-linkages at the telopeptide regions in the spaces around cells, creating a lattice pattern that results in the formation of very strong, mature type II collagen fibers[7].

In cartilage development, proper type II collagen fibril assembly is essential for normal endochondral ossification, the process by which the cartilage template is progressively replaced by bone during skeletal development[41]. Collagen II is important for cartilage formation, while fibril-associated collagens such as collagen IX play roles in cartilage maintenance[41]. The proper organization of these collagen fibrils with other extracellular matrix components determines the mechanical properties of cartilage and its ability to withstand the loading forces experienced during development and throughout life[41].

Abnormal Collagen Structure in Kniest Dysplasia

In Kniest dysplasia, mutations that cause in-frame deletions or other alterations in the COL2A1 gene produce structurally abnormal type II collagen characterized by deletions at the C-terminus of the type II collagen helix that disrupt the normal triple helix configuration[33][56]. These deletions result in shortened collagen monomers that cannot form stable, cross-linked triple helices[3][33]. The presence of these abnormal collagen molecules, when they co-assemble with normal chains, creates a toxic dominant-negative effect in which the misfolded molecules persist in the extracellular matrix and interfere with proper fibril assembly[40]. Electron microscopy studies have revealed that collagen fibril organization in Kniest dysplasia appears severely abnormal compared with age-matched normal cartilages: fibrils are much thinner, of irregular shape, and do not exhibit the characteristic banding pattern observed in normal cartilage[27][33]. These abnormal fibrils reflect defective fibril nucleation and assembly processes, with some studies demonstrating fragmentation and disintegration of collagen fibrils resulting in a web-like pattern and large open cyst-like spaces characteristic of the Swiss cheese appearance[33].

An additional significant defect in Kniest dysplasia involves abnormal processing of the C-propeptide of type II collagen, also known as chondrocalcin[20][27]. The C-propeptide normally plays a critical role in fibril assembly and stabilization, and its proper cleavage and incorporation into the extracellular matrix are essential for normal collagen fibril formation[27]. In Kniest dysplasia cartilage, the C-propeptide is abnormally concentrated in intracellular vacuolar sites within chondrocytes rather than being properly processed and secreted into the extracellular matrix[27]. Although the C-propeptide is detected in the lower hypertrophic zone of the growth plate in association with calcifying cartilage in Kniest dysplasia, its total content is reduced in all cases, and importantly, it is not part of the procollagen molecule, suggesting a fundamental defect in procollagen processing[27]. The absence of C-propeptide in the extracellular matrix of epiphyseal cartilages, combined with the presence of abnormal collagen fibril organization, strongly suggests that the defect in Kniest dysplasia results from the secretion of type II procollagen lacking the C-propeptide and the resulting imperfect fibril assembly[20][27].

Endoplasmic Reticulum Stress and Cellular Responses to Misfolded Collagen

ER Stress and the Unfolded Protein Response

A critical mechanistic pathway in the pathophysiology of Kniest dysplasia involves endoplasmic reticulum (ER) stress and activation of the unfolded protein response (UPR), through which cells attempt to cope with the accumulation of misfolded proteins[15][18]. When abnormal type II collagen molecules are synthesized in chondrocytes, they misfold and accumulate within the lumen of the ER rather than being properly secreted into the extracellular matrix[15][18][54]. An imbalance between the load of unfolded proteins and the processing capacity within the ER leads to the accumulation of these misfolded proteins, triggering endoplasmic reticulum stress as a hallmark response[18]. Upon accumulation of unfolded proteins in the ER lumen, the protein Grp78 dissociates from three key sensor molecules—IRE1, ATF6, and PERK—allowing these sensors to become activated and initiate downstream signaling cascades[18].

The unfolded protein response operates through three main branches: first, by inhibiting general protein translation to reduce the burden of newly synthesized proteins; second, by activating signaling pathways that lead to expression of molecular chaperones and increase the cell's folding capacity; and third, by promoting the degradation of misfolded proteins and reducing their aggregation[18]. In the context of Kniet dysplasia, studies using a col2a1 p.Gly1170Ser knock-in mouse model revealed that misfolded procollagen was largely synthesized and retained in dilated ER, and the ER stress (ERS)-unfolded protein response (UPR)-apoptosis cascade was activated[15]. In this model, heterozygous animals had normal phenotypes with limited ER stress intensity and no abnormal apoptosis detected, whereas homozygous mice expressing the mutant collagen showed dramatic cellular consequences[15].

Chondrocyte Apoptosis and Growth Plate Dysgenesis

The most significant consequence of ER stress in Kniest dysplasia pathophysiology appears to be the induction of chondrocyte apoptosis, which directly contributes to the skeletal abnormalities observed in affected individuals[15]. The early death of chondrocytes occurs prior to hypertrophy and prevents the formation of a hypertrophic zone, thereby disrupting normal chondrogenic signaling pathways and eventually causing the characteristic chondrodysplasia[15]. This apoptotic pathway is activated when ER stress cannot be adequately managed through the normal protective mechanisms of the UPR. The intensity of ER stress appears to determine whether apoptosis occurs, with variations in retained collagen arising from different kinds of mutations influencing stress severity[15].

The growth plate architecture normally consists of three distinct zones: the resting zone containing progenitor cells with slow replication rates, the proliferative zone with flat chondrocytes that replicate quickly, and the hypertrophic zone containing chondrocytes undergoing terminal differentiation[31][34]. In Kniest dysplasia, abnormal chondrocyte differentiation negatively affects linear bone growth by altering the normal cell relationships and provision of growth factors during endochondral ossification[37]. Histochemical studies of growth plate cartilage from Kniest dysplasia patients revealed extensive vacuolar changes occurring within the cartilage matrix and in the lacunae of degenerating chondrocytes[19]. These vacuolar lesions contained chondroitin sulfate but little keratan sulfate or collagen, suggesting a sequence of events initiated by cellular accumulation of abnormal material and progressing to cellular and matrix degeneration[19].

Impaired Extracellular Matrix Organization

Beyond the direct effects of abnormal collagen fibrils, Kniest dysplasia manifests profound abnormalities in overall extracellular matrix organization[54]. In addition to deficient and disorganized collagen fibrils, proteoglycan deposition is abnormal, contributing to the characteristic Swiss cheese appearance visible on histological examination[54]. The proteoglycans, particularly aggrecan, normally interact with collagen fibrils to provide the cartilage matrix with its unique gel-like properties and resistance to deformation through water absorption[32]. When collagen fibril organization is severely disrupted, the normal interactions between proteoglycans and collagen fibrils are compromised, leading to altered tissue biomechanical properties and impaired chondrocyte clustering and function[54].

The disorganization of the growth plate itself is a hallmark pathological finding in Kniest dysplasia[13][33]. Scanning electron microscopy studies demonstrate a disorganized physeal growth plate with soft, crumbly cartilage and diastase-resistant intracytoplasmic inclusions in resting chondrocytes[13][33]. The proliferative and hypertrophic zones of cartilage are notably shorter or indistinguishable, and deposition of cartilage matrix is markedly impaired, with collagen fibrils being fewer and less elaborate than in normal growth plates[37]. This growth plate disorganization directly explains the short stature phenotype observed in Kniest dysplasia patients, as the severely disrupted growth plates cannot support the normal longitudinal bone growth that depends on coordinated chondrocyte proliferation, differentiation, and matrix synthesis[31].

Radiological and Histological Manifestations of Cartilage Pathology

The Pathognomonic Swiss Cheese Appearance

The most distinctive and pathognomonic radiological feature of Kniest dysplasia is the appearance of hundreds of small holes in the bone cartilage, creating a Swiss cheese-like appearance on X-rays[1][2]. This finding reflects the severe disorganization of the cartilage matrix at the microscopic level, resulting from the abnormal collagen fibril assembly and defects in C-propeptide processing[20][27]. The holes represent areas of cartilage matrix degeneration and accumulation of intracellular inclusions within chondrocytes, creating spaces that appear as lucencies on radiographic imaging. Histochemical analysis confirms that these lesions contain chondroitin sulfate but are depleted of normal collagen content, substantiating the biochemical basis for this radiological finding[19].

The Swiss cheese phenotype is not uniformly distributed throughout the cartilage but is particularly prominent in growth plate and epiphyseal cartilage regions where chondrocyte activity is greatest[27]. Interestingly, resting cartilage not adjacent to the growth plate stains more irregularly and shows fewer of the vacuolar lesions characteristic of active growth plate regions, with chondrocytes being enlarged and containing cytoplasmic inclusions but without the prominent vacuolar material seen in growth plate cartilage[19]. This regional variation in pathological findings suggests that areas of active chondrocyte metabolism and matrix synthesis are particularly vulnerable to the toxic effects of abnormal collagen.

Epiphyseal and Metaphyseal Dysplasia

Beyond the Swiss cheese cartilage appearance, Kniest dysplasia manifests with several characteristic radiographic skeletal abnormalities reflecting broad disruptions in endochondral ossification[33][56]. The delayed ossification of epiphyses, with radiographic absence of capital femoral epiphyses in infancy that represent true delayed ossification of large cartilaginous epiphyses termed "megaepiphyses," is a distinctive early feature[33][56]. With skeletal maturation, long bones assume a characteristic dumbbell morphology due to splaying of the metaphyses and development of enlarged, irregular epiphyses[33][56]. The metaphyseal regions show marked irregularity and fluffiness, with loss of normal trabecular bone pattern, indicating severely disrupted mineralization and ossification processes[33][56].

The spine demonstrates characteristic platyspondyly with flattened vertebral bodies and coronal clefts appearing as superior-inferior defects in the midportion of vertebrae during infancy and early childhood[59]. Flattening and squaring-off of the epiphyses of tubular bones of the hands occurs with characteristic narrowing of joint spaces[33][56]. The pelvis shows a trefoil-shaped configuration with marked coxa vara indicating varus deformity of the hip[33][56]. These radiographic changes reflect the widespread disruption of endochondral ossification affecting the entire skeleton.

Joint Pathology and Progressive Arthropathy

Mechanisms of Joint Stiffness and Early-Onset Arthritis

A cardinal feature of Kniest dysplasia is the development of severely restricted joint motion, with enlarged joints causing pain and limiting normal range of motion[3][45]. These joint problems typically lead to early-onset arthritis as affected individuals mature[3][45]. The pathophysiological basis for joint dysfunction in Kniest dysplasia involves multiple contributing factors stemming from the fundamental abnormalities in type II collagen structure and cartilage matrix organization. The abnormal collagen fibrils cannot properly support the articular cartilage, and the defective matrix composition renders cartilage susceptible to degradation. Additionally, the abnormal cartilage development results in improper development of joint structures, with misaligned joint surfaces and structural instability predisposing to progressive degenerative changes.

Hip dysplasia, in which the two hip joints are misaligned or crooked, represents a particularly significant complication affecting multiple patients with Kniest dysplasia[1][24]. The poor development of the cartilaginous femoral head and acetabulum due to growth plate dysgenesis results in anatomically inadequate joint structures that cannot withstand the mechanical loading experienced during development and ambulation. Progressive joint destruction accelerates as the individual ages and continues to load joints with compromised structure and matrix composition. Swollen, stiff, or deformed joints that prevent full movement, particularly affecting knees and elbows, are characteristic of the condition[1][24]. Some patients develop contractures—permanent shortening of muscles and tendons leading to fixed joint flexion deformities—further limiting functional mobility[25].

Cartilage Degradation and Inflammatory Processes

While the primary pathology in Kniest dysplasia stems from abnormal collagen synthesis and matrix assembly, secondary inflammatory processes may contribute to progressive cartilage degradation. Matrix metalloproteinases (MMPs), particularly MMP-13, play important roles in cartilage remodeling during normal development and in pathological cartilage degradation[43]. In normal development, MMP-13 facilitates chondrocyte terminal differentiation by promoting extracellular matrix remodeling and mineralization[43]. However, in the context of abnormal cartilage with defective collagen fibrils and matrix organization, excessive MMP activity could accelerate matrix degradation and progression toward osteoarthritic changes[43].

The abnormal cartilage in Kniest dysplasia may be particularly susceptible to inflammatory insults. Pro-inflammatory cytokines such as interleukin-1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α) induce chondrocytes to produce degradative enzymes including MMPs, nitric oxide, and other catabolic factors that accelerate cartilage destruction[47]. These inflammatory mediators stimulate the production of reactive oxygen species that directly damage articular cartilage[44]. The combination of a structurally defective cartilage matrix with limited capacity for repair, coupled with enhanced susceptibility to inflammatory degradation, explains the characteristic early-onset arthritis and progressive joint dysfunction observed in Kniest dysplasia patients throughout their lives.

Systemic Manifestations and Multi-Organ Involvement

Craniofacial Abnormalities and Their Pathophysiological Basis

Kniest dysplasia manifests with characteristic craniofacial features reflecting the widespread importance of type II collagen in cranial skeletal development[1][2][3][6][25]. The round, flat face with bulging or wide-set eyes and low nasal bridge results from abnormal development of midfacial structures due to impaired endochondral ossification in the cranial base and facial skeleton[1][2][3][6][25]. The abnormal cartilage in these regions cannot properly support normal skeletal development, resulting in characteristic dysmorphic features.

A cleft palate, an opening or gap in the roof of the mouth, occurs in a significant proportion of affected infants[1][3][6][25]. The palatal cleft results from incomplete fusion of the palatal shelves during embryonic development, with abnormal cartilage development in the nasal septum and surrounding structures contributing to the failure of palatal shelf fusion. Beyond structural cleft formation, the palatal abnormalities combined with skeletal abnormalities of the larynx and pharynx can predispose to breathing difficulties. Infants with Kniest dysplasia may experience respiratory issues due to a windpipe that is too flexible, reflecting abnormal cartilage in the laryngeal and tracheal structures[3][45].

Vision Impairment and Ocular Pathology

Vision problems represent a significant component of Kniest dysplasia pathology, with multiple ocular manifestations reflecting the presence of type II collagen in the vitreous of the eye and in the structures maintaining retinal integrity[3][26][39]. Severe myopia (nearsightedness) affects a substantial proportion of patients, with six of seven patients in one clinical series being high myopes[26][39]. The myopia in Kniest dysplasia likely results from abnormal structural development of the eye due to disrupted collagen in ocular connective tissues and possibly from elongation of the eyeball due to abnormal skeletal development of the orbital bones.

Retinal detachment represents one of the most serious vision-threatening complications, occurring in a significant proportion of affected individuals and potentially leading to permanent vision loss[26][39][45]. The retinal detachment in Kniest dysplasia results from thinning of the retina predisposed by cranial structure abnormalities that may elongate the eyeball, combined with abnormalities of the vitreous humor where type II collagen is a key structural component[26][39]. The abnormal vitreous architecture observed in all seven patients examined in one clinical study[26] directly reflects the pathological effects of abnormal type II collagen in this tissue. Variable but consistently abnormal vitreous architecture was a universal finding in patients with molecularly confirmed Kniest dysplasia[26][39].

Additional ocular pathology in Kniest dysplasia includes cataracts, with congenital severe myopia and vitreoretinal degeneration being known associations[29][39]. Some patients develop bilateral quadratic cataracts and subluxed (dislocated) lenses[26]. Possible blindness with disease of the optic nerve and glaucoma may occur[57]. The cumulative burden of vision problems in Kniest dysplasia patients necessitates regular ophthalmologic examination and monitoring, as recommended in comprehensive clinical guidelines[25].

Hearing Loss and Otologic Complications

Hearing loss represents another significant systemic complication of Kniest dysplasia, with six of seven patients in one clinical study having significant hearing impairment[26]. The hearing loss in Kniest dysplasia is frequently conductive in nature, resulting from abnormalities of the ossicular chain and other structures of the middle ear, as type II collagen is a critical component of ear cartilage[1][6][25][28]. The conductive hearing loss may progress with age, necessitating ongoing audiological monitoring[1][25].

The pathophysiological basis for hearing loss in Kniest dysplasia involves abnormal development of cartilage in the ear, including the auditory ossicles (malleus, incus, and stapes) and cartilaginous structures of the external ear[6][28]. The ossicular chain, which normally functions as a mechanical coupling system to transmit sound vibrations from the tympanum to the inner ear, develops abnormally due to impaired endochondral ossification and cartilage matrix defects. Additionally, some patients experience frequent ear infections, which may exacerbate hearing loss[25]. The combination of conductive hearing loss, frequent infections, and structural ear abnormalities creates a substantial burden on auditory function and speech development in affected children[1][25].

Spine and Neurological Manifestations

Spinal Deformities and Vertebral Pathology

The spine is severely affected in Kniest dysplasia, with multiple characteristic abnormalities reflecting the widespread impact of abnormal type II collagen on spinal development[1][24][33][45][56]. Kyphoscoliosis—a combination of excessive forward rounding (kyphosis) and lateral curvature (scoliosis) of the spine—develops commonly in infancy and tends to progress with age[24][33][56]. The platyspondyly (flattening of vertebral bodies) and coronal clefts in vertebrae visible on radiographs represent fundamental abnormalities in vertebral ossification due to disrupted endochondral development[33][56][59].

Cervical spine involvement manifests in some patients as atlanto-axial instability and hypoplastic vertebral bodies with dysplastic pedicles[56]. In one recent case report, vertebral columns of the cervical spine became fused with decreased neck pain during early adulthood, although the patient had experienced neck pain with platyspondyly during adolescence, suggesting progressive spinal changes with age[14]. The instability of spinal structures predisposes to potential spinal cord compression and neurological complications, necessitating careful monitoring and sometimes surgical intervention to stabilize the spine.

Respiratory and Cardiovascular Implications of Spinal Deformities

The severe kyphoscoliosis that develops in Kniest dysplasia can have serious consequences for respiratory and cardiovascular function. The abnormal curvature of the spine restricts the space available for the lungs and heart within the thoracic cavity. The barrel-chested appearance, resulting from shortened trunk stature and spinal curvatures, reflects reduced thoracic volume[1][24][25][55]. Some patients develop respiratory tract infections and experience difficulty breathing related to the restricted thoracic space and abnormal development of cartilaginous structures of the respiratory tract[36][57].

Pathological Features at the Tissue and Cellular Level

Growth Plate Dysgenesis and Chondrocyte Biology

Detailed histological examination of growth plate cartilage from Kniest dysplasia patients reveals profoundly disorganized architecture compared with normal developmental stages[13][19][33]. The resting zone containing progenitor chondrocytes is disrupted, with abnormal cellular morphology and reduced capacity for normal proliferation. The proliferative zone, which normally contains flat chondrocytes organized in vertical columns that divide rapidly to fuel longitudinal bone growth, is severely shortened or indistinguishable from adjacent zones[13][33][37].

The hypertrophic zone, which normally consists of enlarged chondrocytes undergoing terminal differentiation prior to apoptosis and replacement by bone, is either absent or severely stunted[13][15][33][37]. This failure of normal hypertrophic chondrocyte development directly explains the severe growth restriction observed in Kniest dysplasia, as hypertrophic chondrocyte enlargement normally contributes most significantly to longitudinal bone growth through increases in cell volume and height[34]. The normal sequence of endochondral ossification—wherein proliferative chondrocytes undergo hypertrophy, synthesize specific matrix components including type X collagen, undergo apoptosis, and are replaced by invading blood vessels and osteoblasts—is fundamentally disrupted.

The chondrocytes in Kniest dysplasia cartilage demonstrate characteristic cytopathological changes including enlarged cells containing abundant cytoplasmic inclusions and vacuoles[19][27]. These vacuolar lesions within chondrocytes represent accumulation of abnormal material, likely including misfolded collagen and other extracellular matrix components that have been endocytosed or retained intracellularly due to failed secretion[15][27]. The extensive vacuolar changes observed throughout the growth plate and in adjacent resting cartilage suggest a sequence of events initiated by cellular accumulation of abnormal material and progressing to cellular degeneration[19].

Impaired Proteoglycan and Collagen Interactions

The normal extracellular matrix of cartilage represents a highly organized three-dimensional network of collagen fibrils, proteoglycans, and other proteins that work in concert to provide the tissue with its unique mechanical properties[32][35]. Proteoglycans, particularly the large aggregating proteoglycan aggrecan, bind to hyaluronic acid in the extracellular space and interact extensively with collagen fibrils to create a gel-like substance that can absorb large amounts of water and resist compression[32][35]. This proteoglycan-collagen interaction is essential for normal cartilage biomechanics and for regulating chondrocyte behavior through altered matrix composition.

In Kniest dysplasia, the severe abnormalities in collagen fibril structure and organization disrupt the normal interactions between collagen fibrils and proteoglycans[27][33]. The absence of C-propeptide in epiphyseal cartilage extracellular matrix and its intracellular accumulation in vacuoles suggests that the procollagen processing machinery is fundamentally disrupted[27]. The septa of lesions visible on histochemical analysis contain chondroitin sulfate (a proteoglycan component) but little keratan sulfate or collagen, demonstrating a fundamental disruption in matrix composition[19]. The abnormal ratio of proteoglycans to collagen, combined with defective collagen fibril architecture, renders the cartilage matrix incapable of properly supporting chondrocyte function or withstanding mechanical loading.

Molecular Mechanisms of Disease Severity and Genotype-Phenotype Correlation

Dominant-Negative Effects and Haploinsufficiency

The pathophysiological mechanisms underlying type II collagenopathies, including Kniest dysplasia, operate through two principal molecular mechanisms: dominant-negative effects and haploinsufficiency[37][40][54]. Dominant-negative mutations, which account for the majority of COL2A1 mutations causing Kniest dysplasia, involve production of abnormal collagen chains that associate with normal chains to form non-functional collagen molecules[40][54]. Because type II collagen molecules consist of three identical alpha-1(II) chains twisted together into a triple helix, the incorporation of even one mutant chain into a collagen molecule can disrupt the entire structure and function of that molecule, rendering it non-functional[40][54]. This explains why heterozygous individuals with only 50 percent abnormal collagen alleles can manifest severe disease phenotypes—the mixing of normal and abnormal chains during triple helix assembly results in a substantial proportion of defective collagen molecules.

In contrast, haploinsufficiency represents a mechanism due to nonsense substitutions or out-of-frame deletions resulting in premature stop codons that cause reduced synthesis of normal collagen[37][40]. These mutations are generally associated with milder phenotypes than the dominant-negative mutations characteristic of Kniest dysplasia[37]. The distinction between these mechanisms explains why different COL2A1 mutations can produce varying severity of disease, with in-frame deletions associated with Kniest dysplasia representing mutations that produce truncated but still-expressed abnormal collagen chains capable of dominant-negative effects.

Anatomic Location of Mutations and Disease Severity

The location of COL2A1 mutations within the gene influences the severity of the resulting phenotype. Mutations spanning exons 12 through 24 are particularly associated with the Kniest dysplasia phenotype, with this region representing a critical domain for proper collagen structure[14][33][37]. Some evidence suggests that mutations resulting in specific amino acid substitutions or deletions in particular regions of the collagen triple helix may produce more severe phenotypes than others, though a clear genotype-phenotype relationship has not been fully elucidated[14][37]. The specific splice mutations identified in individual patients, such as the c.1266+2T>A mutation, produce molecular consequences including both out-of-frame and in-frame transcripts, with functional studies assessing the pathogenicity of variants being needed to fully understand how particular mutations lead to disease severity[14].

Current Clinical Understanding and Therapeutic Implications

Multi-System Disease Management Approach

The multi-system involvement in Kniest dysplasia necessitates comprehensive, coordinated medical management involving multiple specialist disciplines[1][24][25]. Treatment is typically determined on a case-by-case basis, with the specific manifestations and severity in each individual patient guiding therapeutic decisions[1][24]. For orthopedic complications including scoliosis, treatment decisions consider the severity of the spinal curve, its location within the spine, the patient's age and stage of growth, and the functional impact on the individual[1][24]. Non-surgical options including bracing and physical therapy may be attempted for mild deformities, while surgical options such as spinal fusion or implantation of growing rods to stabilize the spine as the child continues to grow may be necessary for severe curves[1][24].

Hip dysplasia and other joint problems are managed through orthopedic specialists with knowledge of the particular pathology in Kniest dysplasia. Some patients require surgical correction of clubfoot deformities, which are present at birth in some cases[1][24][56]. Children with cleft palate require surgical repair, while those with mild hearing loss may only require monitoring to ensure the condition does not worsen[1][24]. Regular ophthalmologic examination is essential to detect vision problems, including myopia that may be managed with corrective lenses, and to monitor for retinal detachment which may require surgical intervention[1][24][25].

Future Research Directions

Recent advances in understanding the molecular mechanisms of Kniest dysplasia and other type II collagenopathies, particularly the recognition of endoplasmic reticulum stress and unfolded protein response activation as central pathogenic mechanisms, suggest potential future therapeutic targets[15][18][54]. Molecular chaperones that could potentially aid in the degradation and secretion of mutant proteins, or small molecules that could enhance the unfolded protein response capacity of chondrocytes, represent potential therapeutic avenues[54]. Understanding the cell-autonomous and non-cell-autonomous effects of mutant collagen expression in heterozygous carriers, combined with improved characterization of disease-specific molecular signatures through omics-based approaches, may enable development of genotype-specific therapeutic interventions[54].

Conclusion

Kniest dysplasia represents a severe skeletal dysplasia arising from heterozygous mutations in the COL2A1 gene that profoundly disrupt the synthesis, processing, assembly, and function of type II collagen throughout the body. The pathophysiology encompasses multiple interconnected mechanisms including production of structurally abnormal collagen chains that exert dominant-negative effects on collagen fibril assembly, abnormal processing of collagen C-propeptides leading to defective extracellular matrix organization, accumulation of misfolded collagen in the endoplasmic reticulum triggering cellular stress responses and apoptotic pathways, and severe disorganization of growth plate architecture preventing normal endochondral ossification. These molecular and cellular pathological processes manifest as the characteristic skeletal dysplasias including severe short stature, dumbbell-shaped long bones, platyspondyly with coronal vertebral clefts, the pathognomonic Swiss cheese cartilage appearance, and progressive joint stiffness leading to early-onset arthritis. Beyond skeletal manifestations, Kniest dysplasia affects multiple organ systems including the eye causing myopia and retinal detachment, the ear resulting in conductive hearing loss, and craniofacial structures producing characteristic dysmorphic features and cleft palate. The progressive nature of many complications and the multi-system involvement necessitate comprehensive, coordinated medical management from early infancy through adulthood. Continued investigation of the molecular mechanisms underlying ER stress and cellular responses to mutant collagen expression, combined with improved understanding of genotype-phenotype correlations, may ultimately enable development of targeted therapeutic interventions to ameliorate the devastating skeletal and systemic complications of this rare but severe genetic disorder.